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Abstract
Purpose
To determine in a population with lower extremity wounds associated with vasculopathy
if: (1) previously proposed clinical signs of infection are valid indicators of wound
infection; (2) low frequency (22.5 kHz) contact ultrasound debridement (LFCUD) is well
tolerated and feasible to apply in a nurse-led vascular wound clinic; (3) healing outcomes
are improved for patients receiving LFCUD in comparison to patients receiving usual
care (UC).
Methods
A total of 80 patients were in the study. First, a pilot group of ten patients were followed
to determine tolerability, feasibility and wound response of 4 weekly LFCUD treatments.
Then 70 patients were randomly allocated into LFCUD plus UC (n= 33), or UC (n = 37).
Clinical signs of wound infection were compared to tissue culture and physician
evaluation. Outcomes included mean percentage decrease in wound surface area
(%WSA), change in wound appearance (revised Photographic Wound Assessment Tool
[revPWAT]), and change in pre- to post-treatment pain scores by Visual Analogue Scale
(VAS).
Results
No individual clinical sign was both highly sensitive and specific to indicate infection.
The presence of three combined signs yielded the highest positive likelihood ratio (7.2),
but absence of signs was uninformative. LFCUD is well tolerated and feasible for nurseapplication. After 4 treatments the between-group change in %WSA was not statistically
significant. The LFCUD group showed a significant linear trend in WSA reduction with
each treatment visit (p = < 0.01), and a significant improvement in wound appearance for
the LFCUD group (4.36 revPWAT points, 2.07-6.66, 95% CI, p = 0.01) compared to UC.
There was no significant decrease in wound infections between groups. There was a
significant decline in VAS pain score of 16.56mm (± 32.5, t(31) = 2.89, p = 0.007, 95%
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CI) in the LFCUD group but this was not significant in the UC group. There were no
treatment-related adverse effects.
Conclusions
Clinical signs of infection are specific, but inadequately present for screening the
vascular population. LFCUD is well tolerated and resulted in superior wound appearance
with consistent trending of WSA reduction. It was not determined that LFCUD reduces
infection, improves healing times or supports wound closure.

Keywords
Randomized Controlled Trial, Low Frequency Ultrasound, Wound Debridement, Chronic
Wound Healing, Wound Infection, Vascular.
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Chapter 1: Thesis Introduction

The aim of this doctoral research is to improve wound care treatment for patients with
vascular disease. This research, comprised of three comprehensive and clinical studies,
responds to a growing need in Canada to address the needs of a particular population with
challenging health needs. With a view to improving access to care and improving healing
outcomes for patients with vascular disease, this study aims to better identify and address
signs of wound infection, and treat wound infection using ultra sound assisted
debridement.
The alarming cost of caring for wounds in Canada is estimated at $3.9 billion per year or
around three percent of national healthcare expenditures, and due to an aging population
this figure is expected to increase by 30% by 2020.1In Ontario alone, the cost of lower
extremity wound care is estimated at $511 million annually,2 and around 50% of home
care nursing visits are related to some aspect of wound care.3 Notably, when vascular
disease is present, the time to heal a wound extends considerably.4 For example, without
vascular surgery, just 25% of lower extremity wounds will be healed at six months, and
50% at one year.5 Extended healing times reduce quality of life, require more health care
resources, and allow greater opportunity for complications, including infection, to occur.
Furthermore, the prevalence of peripheral vascular disease (PVD) is thought to be
increasing.6 This is because PVD is strongly linked to other prevalent conditions such as
diabetes, increased age, hypertension, dyslipidemia, and chronic renal failure.7 Patients
requiring surgery to address PVD have readmission rates three times higher when a
wound is present prior to vascular surgery, and in the United States, the cost of each
vascular readmission is estimated to add $12,400 US dollars to the cost of care.8 Further,
given that any improvement in post-operative blood flow may have limited durability,9
effective wound therapies are needed within a window of opportunity after surgery.
A diagnosis of diabetes is a common predictor of PVD and interferes with healing
considerably. Patients with diabetes have an increased risk of lower extremity arterial
disease by two to four times, and increased wound prevalence of almost six times.
Diabetes impairs the ability to fight bacteria in the wound with

diabetes-related soft tissue infection or bone infections (osteomyelitis) estimated to be
responsible for around 25% of all hospital admissions for persons with diabetes.10
For patients with diabetic foot ulcers, infection has been implicated in non-healing
wounds when arterial disease is present, but is not thought to prevent healing if perfusion
is normal.4 Despite the fact that infection may lead to serious consequences including
advancing illness, amputation and death,11 few studies have focused on identifying and
treating infections particular to patients with vascular disease. Given that limited vascular
supply is known to starve the wound tissue of basic needs and decrease the amount of
antibiotic and other treatments that will be delivered to a wound,12 further research is
required to guide the prompt diagnosis of infection and to determine which treatments are
most effective for this vulnerable population.
Not only is there a need for better recognizing and addressing infection, there is also a
need to explore effective forms of wound treatment for this high risk population. At
present, there are few effective methods to support wound healing in patients with
vascular disease. Advanced wound products and biophysical therapies are known to
address micro-imbalances in the wound environment and can be effective in advancing
chronic wounds towards healing.13 However, skilled and meticulous surface preparation
is also required, which, in clinical practice, may be frequently unavailable. Therefore the
true clinical potential of these therapies may be underachieved. Taken further, the
vascular population is often excluded from advanced wound therapy trials, and so the
effectiveness of these promising therapies on this population is yet to be determined.
One possible solution could be to improve the quality of, and access to, debridement
procedures for patients with vascular disease. These procedures prepare, cleanse and
stimulate the wound surface, and are an essential part of preparing the wound for
healing.14-16 A debridement method that is easy to apply, safe, and comfortable for the
patient could improve access to care for the vascular patient, and possibly improve their
healing outcomes. However, at present, the availability of any debridement procedure
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remains a barrier since the procedure requires a supported clinical environment, specific
sterile equipment, clinicians with advanced clinical skills, and well-developed policies
(that are, to date, underdeveloped).16
Responding to the needs of a growing, yet under-researched population, the purpose of
this study is to examine whether currently accepted clinical signs of infection are reliable
indicators in a population with PVD. We also evaluate a method of ultrasound assisted
debridement that might improve access to care, and possibly produce better healing
outcomes. We explore whether accurately identifying infection and then offering
aggressive and timely wound therapy in the outpatient setting could potentially reduce
some vascular and diabetes-related acute care admissions, morbidity, days of in-hospital
stay and associated costs.
The purpose of this thesis is to evaluate clinical signs of infection noted in patients with
vasculopathy, and to investigate a potential treatment method for this high risk
population. The body of work is presented in three chapters as follows.
In Chapter 1 of this thesis, we investigate the applicability of previously proposed signs
of infection for a vasculopathic population. This chapter responds to the need to research
patients using a vascular surgery service, who may have disease that are more advanced
and have more advanced wound pathologies. At present, it is unknown how well signs of
infection perform as vascular disease advances. Responding to this need, we explore
whether the classical signs of infection (e.g., purulent drainage, heat, redness, swelling
pain)17 occur in patients with vasculopathic wounds, who are prone to having ineffective
inflammatory responses.18 Additionally, we explore other previously proposed subtle
signs of infection, which are used in composite tools to identify infections in other
populations.19
Chapter 2 presents a small prospective pilot study focused on the weekly application of a
newer, low frequency contact ultrasound (LFCUD) system of debridement. Ultrasound
treatments have been previously found to stimulate mechanisms of healing20, 21; 22, 23 and
to have antibacterial properties. In this pilot study, ten patients received four weekly
LFCUD treatments that were applied by a nurse specialist. Attending to patient tolerance
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and feasibility, we measure pain, adverse events, changes in wound appearance, and
changes in wound surface area (WSA). We find LFCUD is attractive for this population,
because it selectively targets the dead (necrotic) tissue, and reportedly causes minimal
pain and bleeding. 24-26 We propose LFCUD could be applied by a specialist nurse in a
supported environment without need for operating room space.
In Chapter 3, we describe our randomized controlled trial that took place after our pilot
study to determine treatment effects. Patients were assigned to the LFCUD plus usual
care (UC) group or to the UC group. All patients were followed by the vascular surgery
department for issues related to lower extremity wounds. As a part of our study, we
measured treatment effects on wound contraction, wound appearance, wound closure,
and other complications.
This goal of this thesis is to provide new knowledge regarding infection appearances and
treatment responses in a population with advancing vascular disease. Since patients with
vascular disease are prone to infection and the development of necrotic debris, we
explore the effect of a novel treatment for vascular wounds. We explore if debridement
assisted by ultrasound can address particular healing barriers that these patients often
face. While this population is under-researched in previous clinical trials due to their
complicated health presentation, we believe that investigating the particular needs of this
population is critical since the complicated nature of their disease may alter response.
Additionally, given the microcellular imbalances that occur with advancing vascular
pathology, patients with vascular disease may have more to benefit than a general
population from emerging advanced wound therapies which may address cellular
response.
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Chapter 2: Validity of clinical signs of wound infection in
patients with vascular disease
2.1

Introduction

People with vascular disease are an under-researched population who are vulnerable to
the effects of wound infection. It has been estimated that over one in 20 ambulatory
people over 50 years of age across Canada are affected by vascular pathology, which
results in poorly functioning blood vessels.1 Types of vascular pathology include
occlusive arterial disease, microcirculatory pathologies, diabetic neuropathic changes,
and venous insufficiency. Symptoms are associated with the causative factor, and include
pain or fatigue in the legs, skin breakdown, fluid accumulation in the legs (edema) and
poor wound healing.2-5
Vascular disease influences wound healing in part because adequate blood flow is
essential to produce an efficient inflammatory response necessary to promote early
wound healing. Critically, the cells that are the basic building blocks of tissue rely on
blood flow to deliver essential life-support elements such as oxygen and nutrients.6
Oxygen plays a significant role in tissue repair. Chronically low oxygen (referred to as
chronic hypoxia), occurs with arterial, venous and cardio-respiratory pathologies, and
critically affects tissue repair.7 Importantly, an oxygen gradient (between welloxygenated blood and the damaged central wound tissue) is essential to drive the
formation of new tissue, which is known as granulation tissue.7, 8 However, people with
vascular disease have a lower oxygen gradient, since there is less oxygen available from
central blood supply, in addition to less oxygen available in the wound environment.
Chronic hypoxia in people with vascular disease may be attributed to a combination of
vascular changes including occlusive arterial disease, microcirculatory pathology, and the
presence of edema and venous insufficiency.8
Any interruption of oxygen and nutrient supply may rapidly lead to cellular demise. This
results in an extending mass of necrotic material which becomes a food source for
bacteria and increases the risk of infection. Furthermore, a hypo-perfused wound permits
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the spread of bacteria or the development of infections since counter measures, including
the availability of leukocytes, are impaired.9 Therefore, infection is a frequent and serious
problem for patients with vascular disease, and the threat of advancing wound infection
can necessitate surgical procedures and even amputation as life-saving procedures.
Unfortunately, the prognosis following major amputation is poor. For example, after two
years, an estimated 40% of patients will achieve mobility, 30% will die, 15% will convert
to above knee amputation, 15% will undergo amputation of the other leg, and only 60%
will heal the surgical amputation wound by primary closure.10 Therefore, early
identification of infection in patients with vascular disease is highly desirable to avert
poor outcomes.
When blood vessels are diseased, revascularization procedures such as bypass and
angioplasty are commonly used for the vascular surgery population to restore blood flow.
That said, while these procedures may improve local perfusion and healing potential, the
underlying systemic pathology is not resolved.11 Calcified vessel wall deposits and
atherosclerotic plaques may affect the movement, function and communicative abilities
of components such as white blood cells, growth factors, and proteases that are essential
for tissue restructure. To date, it is unknown to what extent the inflammatory response
may be restored after varying degrees of re-perfusion. Further, it is unknown if patients
who have received vascular procedures demonstrate inflammatory signs of infection that
may be noted in other populations.

2.1.1

Wound Infection

Wound infection occurs when microorganisms overwhelm the host defense system and
invade tissue, causing a local and systemic response.12 Wound infection is traditionally
marked by the presence of purulence and/or by the presence of two inflammatory signs
such as pain, erythema, heat or edema.13 However, it is widely acknowledged that
inflammatory signs may be diminished in immunocompromised patients and so these
signs may be unreliable.12
Testing for bacteria by culturing sample obtained from the wound is the most available
and objective method to measure bacterial burden. However, using culture alone is not
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suitable to identify wound infection as methods of obtaining and analyzing cultures may
be inconsistent and the area sampled may not fully reflect the wound environment.14
There is also an ongoing debate about the best method to obtain the culture. While
obtaining a portion of tissue for sampling is viewed as the gold standard,12 wound surface
swabs such as the Levine technique15 are more widely available, more comfortable for
the patient, and correlate well with aerobic and anaerobic tissue culture.16 After 30 days,
a tissue culture may provide more accurate information about persistent and resistant
strains of bacteria that remain active in the wound.17 It is possible that this late result
occurs from the deeper tissue samples since a surface swab may not access nonplanktonic and persistent biofilm bacteria.18 These persistent types of bacteria are hard to
identify, but have been estimated to be present in 60% of chronic wounds.19
While there have been various developments, recent genetic methods of identifying
bacteria suggest only a small percent of bacteria may be culturable at all.18 Further, while
the information gained from the culture is essential for guiding antibiotic therapy, the
objective result does not measure the degree of host insult or ability to defend against the
bacteria. Therefore, the diagnosis of wound infection, particularly for vulnerable patients
with vascular disease, requires a comprehensive and clinical evaluation.
Identifying wound infection by appearance is an appealing option since culture only
provides partial information and requires a time-consuming laboratory analysis. While
identifying particular clinical signs would ideally identify a patient reaction to the
bacteria, this approach assumes a well-functioning inflammatory response.
Unfortunately, patients with vascular disease may lack the physiological capabilities for
that needed response.12 Therefore, to date, researchers are uncertain if the signs of
infection that have been associated with other populations are applicable to members of
the acute care vascular surgery population.

2.1.2

Subtle Signs of Infection

Interestingly, many chronic wounds of various etiologies do not seem to show the classic
inflammatory signs of infection that form the basis of the traditional Infectious Diseases
Society of America (IDSA) infection classification.20 Previous authors have proposed
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there are additional and subtle signs of wound infections including delayed healing,
discoloration, friable granulation tissue (e.g., tissue that bleeds easily), unexpected pain
or tenderness, pocketing of the wound base, bridging of the epithelium or soft tissue, and
abnormal smell.21 To validate these signs for chronic wounds, a Clinical Signs and
Symptoms Checklist was compiled, and each sign was compared against a sample of
cultured tissue to achieve equal or greater than 105 organisms per gram of wound tissue of
bacterial growth, which is considered the gold standard measure of infection.22 The study
consistently found that pain was absent in all patients without infection, meaning that the
presence of pain would be highly likely to indicate infection. However, the study also
found that no single sign was present in all infected wounds, meaning no one sign could
be used to screen patients for infection.

2.1.3

Composite of Signs of Infection

Since subtle signs were more frequently found yet no single sign represented infection, a
composite method made of a combination of signs was proposed. Subsequently, it was
found that a composite list of signs performed better than individual signs, when
comparing positive tissue results (greater than106 organisms per gram of tissue) in
diabetic foot ulcers.23 Pain was, again, found to be absent in all uninfected patients.
Building on the approach of identifying composite signs, other researchers developed and
validated a mnemonic format of the signs termed “NERDS and STONEES” to increase
the clinical applicability and to support clinicians in identifying the clinical signs.24 The
mnemonic, “NERDS,” refers to characteristics of superficial bacterial burden: Nonhealing; Exudate; Redness (friability); Debris; and Smell. “STONEES” refers to
characteristics of deep tissue infections: Size bigger; Temperature; Os (probes to bone);
New areas of breakdown; Exudate increase; Erythema with Edema; and Smell. When
comparing the semi-quantitative cultures of wound fluid swabs, the study found the
presence of three signs associated with NERDS or STONEES was indicative of
superficial or deeper bacterial growth, respectively. Interestingly, wounds that had debris,
increased serous exudate, and friable granulation tissue were five times more likely to
have scant or light culture growth which they termed “superficial critical colonization.”
Additionally, wounds with an elevated temperature were eight times more likely to be
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infected as evidenced by moderate or heavy culture growth. However, this study
excluded patients with advancing vascular disease (because of possible effects on wound
appearance and progress). These authors have since suggested a new and similar
composite tool, “UPPER and LOWER”, which is described in detail later, but is yet to be
validated. This, again, serves as an impetus for examining the individual and composite
signs of wound infection among the vascular surgery population.
Further complicating the issue, there is a global demand to reduce the indiscriminate use
of antibiotics that are responsible for the spread of multi drug resistant organisms
(MDROs).25 Despite this need to reduce antibiotic prescriptions and curb what is referred
to as a global antibiotic crisis, precise, point-of-care diagnostic tests for wound infection
are not yet available. Given that the under treatment of wound infections can have serious
consequences for vulnerable patients (as described above), clinicians are therefore faced
with a dilemma. They must choose between aggressive antibiotic prescription practices
that may encourage MDRO development or less aggressive approaches that may
inadequately address a latent infection. Not only is there a need for an improvement in
diagnostic techniques, there is also a need for population-specific approaches that account
for and respond to particular patient characteristics.26 This study aims to develop a
method to identify wound infection in patients with common characteristics of vascular
disease while offering a comprehensive and clinical approach to these demands.

2.2

Research Purpose

While introducing customized assessment measures for specific populations may seem
unwieldy, there is a need to confirm clinical tools are transferable to specific and
vulnerable populations. To date, the impact of advancing illness, including vascular
disease and associated compounding health problems, on infected wound appearance is
not well understood. The aim of this study is to examine the validity of classical and
subtle signs of wound infection in patients with peripheral vascular disease (PVD), who
often require surgical intervention and may have a poor healing potential due, in part, to
the high risk of wound infection. This study asks the following questions about patients
with vasculopathy:
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1. Are there individual classical and subtle signs that are associated with the
presence of wound infection, as identified by an Infectious Disease physician
and/or by a positive tissue culture?
2. Are there composite signs (that incorporate combined signs of infection) that
are associated with presence of wound infection, as identified by an Infectious
Disease physician positive diagnosis and/or by a positive tissue culture?
3. Is there an improved combination of signs that might serve the vasculopathic
population better than existing composite methods?
This study was approved by the Ottawa Hospital Research Institute Research Ethics
Board, and the Western University Research Ethics Board (See Appendix 1). The study
involved 78 participants with PVD and lower extremity wounds. Bringing together the
expertise of medical professionals, including an Enterostomal Therapy Registered Nurse
(ET RN), a team of vascular surgeons and an Infectious Disease (ID) physician, this
project aims to identify wound infections in patients with vascular disease and improve
diagnostic measures.

2.3
2.3.1

Methods
Recruitment

Patients were recruited at an outpatient clinic and in-patient ward of a vascular surgery
service provided in in Ottawa, Canada. All patients who met inclusion criteria were
approached consecutively by one of six vascular surgeons. Patients were eligible if they
were English speaking adults (18 years or older), and had a full thickness wound of
determined etiology that was below the knee and measured greater than 1cm2. Patients
were excluded if they had severe arterial insufficiency which was defined as absence of
palpable pedal pulses combined with ankle brachial pressure index (ABPI) less than or
equal to 0.3; toe pressure less than or equal to 20mmHg; or transcutaneous oxygen
measure less than or equal to 20 mmHg. Patients were also excluded if they: had an
acute limb or life-threatening infection; had an exposed vascular graft, blood vessel, bone
or tendon in the base of the wound; were medically unstable or had a condition that
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reduced life expectancy; were receiving hyperbaric oxygen; had a cardiac pacemaker or
defibrillator; were immunosuppressed; or had malignancy in the wound.

2.3.2

Perfusion Assessment

Perfusion was determined by ABPI, toe pressure , transcutaneous oxygen measure,
computed tomography angiography or conventional digital subtraction angiography, as
determined by the vascular surgeon and in keeping with comprehensive vascular
assessment.27 In the circumstances where more invasive tests had been performed, ABPI
and toe pressure testing were not employed since perfusion status was already determined
and this population has a high incidence of unobtainable Doppler tests due to calcified
blood vessels. One of six vascular surgeons evaluated patients and interpreted tests to
determine if perfusion was optimized, and if patients were eligible to participate.

2.3.3

Measuring Individual and Composite Signs

Clinical signs recorded in this study were recorded by a single assessor, who was an ET
RN with graduate education in the field of wound care. One wound per patient was
assessed and the presence or absence of individual and composite signs (e.g., heat,
increasing pain, erythema, edema, purulent exudate, increasing wound size, delayed
healing, wound breakdown, odour, serous exudate, debris, friable granulation, induration)
was noted as dichotomous data. See Table 1 for an overview of the individual and
composite signs measured.
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Table 1. Definitions Used for Signs of Infection

Signs
Heat

Definition
Heat was defined as wound temperature > 3o F from a point
approximately 10 cm at the distal aspect of the peri-wound skin.
Increasing pain was the new elevation of pain > 50mm on the Visual
Analogue Scale (VAS), and/or patient described increased pain since
last assessment.
Erythema was redness >2 cm beyond the wound edge.
Edema was presence of swelling within 4cm of the wound edge that
demonstrated pitting indentation with locally applied pressure.
Purulent exudate was the visible appearance of creamy-yellow
exudate.
Increasing wound size was larger wound since last since the last visit.

Increasing
pain
Erythema
Edema

Purulent
exudate
Increasing
wound size
Delayed
Delayed healing was determined by less than 20% to 40% wound area
healing
contraction in the previous two to four weeks (as retrieved from
medical documents or by patient description if data were
unavailable).
Wound
Wound breakdown was small open areas in newly formed epithelial
breakdown tissue that were not caused by re-injury or trauma.
Odour
Odour was noticeable unpleasant smell after dressing removal.
Serous
Serous exudate was > 50% surface area of removed dressing saturated
exudate
clear wound fluid.
Debris
Debris was the presence of slough, eschar, necrotic or non-viable
tissue.
Friable
Friability was determined by observation of bleeding with gentle
granulation touch of sterile instrument.
Induration Induration was the presence of hard mass with loss of tissue pliability
in the peri-wound region.
Abbreviations:
100mm).

o

F = degrees Fahrenheit; cm = centimeter; VAS = Visual Analogue Scale (in millimetres out of a total
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2.3.4

Measuring Wound Size and Temperature

After taking the individual and composite measurements, wound size was determined by
tracing the wound edge on clear acetate which was then measured by planimetry
(Visitrak®, Smith & Nephew, UK). Wound photographs were taken with a ruler in the
image using a Canon Rebel 300D EOS, 8 megapixel resolution, 60mm macro lens digital
camera with a ring flash and automatic focus. Wound temperature was measured with an
infrared thermometer (Thermotrace®, Prizm Medical, Dunwoody, GA) at the midpoint of
the wound. It was then compared to the area approximately 10cm distal to the wound on
the ipsilateral limb.

2.3.5

Analyzing Tissue Sample

One ID physician estimated each patient’s wound for infection. After cleansing with
physiological saline solution, the tissue sample was retrieved by either a 3mm punch
biopsy or scalpel. In small wounds where biopsy was not attainable, the physician used a
scalpel to obtain the tissue sample from the most central part of the wound that was
accessible. The ID physician comprehensively evaluated the wound, measured patient
symptoms, and determined whether the wound was infected or not-infected.
Subsequently, when the laboratory analysis of the tissue sample was available, both the
ID physician’s evaluation and the tissue culture result were used to determine whether or
not the wound was infected. This reference standard was chosen since it is commonly
used in clinical practice to determine whether antibiotic treatment is required. The tissue
sample was sent by the ID physician immediately to a local laboratory in a sterile
container without transport media. The species and quantity of bacteria were determined
through a clinical laboratory semi-quantitative analysis method. As a part of the process,
samples were weighed, homogenized, serially diluted then smeared onto plated standard
media and cultured under aerobic and anaerobic conditions. A positive culture was
defined as laboratory-reported moderate or heavy bacterial growth detected by isolation
in three or four quadrants.
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2.3.6

Prescribing Antibiotic Therapy

Lastly, after receiving the laboratory results, the same ID physician prescribed antibiotic
therapy as per the Infectious Diseases Society of America’s (IDSA) Practice Guidelines
for Skin and Soft Tissue Infection28 and Diabetic Foot Infection.13 In many cases, this
physician had to decide whether to continue or extend current antibiotic therapy.

2.3.7

Individual and Composite Signs

Individual and composite signs were designated as present or absent, and were calculated
as dichotomous data. Specifically, for the IDSA combination of signs, the presence of
two or more signs of inflammation (e.g., pain, erythema, heat or edema) and/or purulent
exudate was considered indicative of infection. Using the aforementioned NERDS and
STONEES combination, we considered cases with two, three or four signs present as
indicative of a wound infection. We also used the mnemonic UPPER and LOWER,
which had not yet been validated, to examine the two, three or four signs indicative of
infection. The signs in “UPPER” refer to superficial bacterial burden: Unhealthy tissue;
Pain; Poor healing; Exudate; and Reek. The signs in “LOWER” are: Larger in size;
Osseous tissue; Warmth, Edema and Redness.
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2.3.8

Sensitivity and Specificity

Sensitivity was calculated by dividing the true positive scores by all the actually infected
wounds (true positive/ true positive + false negative). Specificity was determined by
dividing the true negative scores by all truly non-infected wounds (true negative/ true
negative + false positive). See Table 2 for definitions of the terms.
Table 2. Presence of Individual and Composite Signs: Definitions for Results

Result

Definition

True positive
(TP)

True positive means that the sign was present when the wound was
infected.

False Positive
(FP)

False positive means that the sign was present, but the wound was
not infected.

False negative
(FN)

False negative means that the sign was absent, but the wound was
infected.

True negative
(TN)

True negative means that the sign was absent and the wound was
not infected.
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2.3.9

Likelihood Ratio

The Likelihood Ratio (LR) is the proportion of probability of having a test result that
correctly identifies the condition compared to the probability of returning a false result.
Thus, formulae for LRs are derived from the sensitivity and specificity data as follows:
LR+

= True Positive Rate =

Sensitivity

False Positive Rate

1 – Specificity

LR – = False Negative Rate = 1 – Sensitivity
True Negative Rate

Specificity

The LR is used to determine the extent that the result of a test will increase or decrease a
pre-test probability of the target disorder.26 The translation of the pre-test to post-test
probability was accomplished using a nomogram calculator,29 which involves placing a
ruler from the pre-test probability across the LR to reveal the post-test probability. LRs
were not calculable when the numerator or denominator was zero.

2.3.10

Odds Ratio

We also calculated the odds ratio (OR). The OR describes the odds of infection when
sign is present compared to odds of infection when a sign is absent.26 The OR was
calculated as (TP x TN)/ (FP x FN) and presented with 95% confidence intervals.

2.3.11

Statistical Analysis

Data were entered into a computer research data base (Empower Health Research,
London, Canada), and exported directly to the statistical software package (SPSS,
Version 23.0, Armonk, NY) for analysis. The difference in demographics and physical
characteristics of patients assigned to groups that had infected or non-infected wounds
was determined by the Independent Student’s t-Test for continuous variables and X2 Test
for categorical variables. The Fisher’s Exact Test was used when any categorical count
was equal to or less than five. Statistical significance was considered at p = <0.05. A
positive Likelihood Ratio of greater than five or negative Likelihood Ratio of less than
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0.2 was considered the threshold of clinical importance since it would alter the post-test
probability sufficiently to affect treatment.26

2.4

Results

The study involved 78 participants, who consented to participate and were recruited
between December 2013 and May 2015. The characteristics of the 78 subjects are
presented in Table 3. Of the participants, 22 (28.2%) were diagnosed as having a wound
infection using a combination of the ID physician’s assessment and/or a positive culture
result. Sixty-five patients (83.3%) had wounds with light growth or no growth on culture,
and 13 (16.7%) had moderate or heavy growth. Nine patients were identified as infected
by the ID physician without moderate or heavy growth on the culture. Patients diagnosed
with infection tended to have had longer duration diabetes, wounds on the heel or leg,
and fewer re-vascularization procedures, but these differences were not statistically
significant. However, patients with infection had higher Body Mass Index (BMI) which
was the only characteristic that was statistically significant, (p = 0.010).

21

Table 3. Patient Demographics by Wound Bacterial Burden from Semi-quantitive Culture

Age (Years)
Male
BMI
Wound Duration
(Months) (n= 76)
Wound Location
Toe/ Toe
Amputation Site
Mid-Foot/Plantar
Heel
Malleolar
Leg
Diabetes
Duration Diabetes
(Years) (n= 52)
Anti-coagulant
Medication
Antibiotic Medication
Hemoglobin (n = 77)
Albumin (n = 70)
Arterial
Insufficiency
Previous
Angioplasty
LE Bypass Graft
Previous
Amputation
Major
(Transtibial/
Transfemoral)
Distal
(Transmetatarsal/
Digital)
Pedal Pulse
Palpable

Total Sample

Infected

Non-infected

(n = 78)
65.76 ± 10.36
78.2 (61)
26.80 ± 6.19
14.13 ± 25.78

(n = 22)
62.41 ± 6.67
81.8 (18)
29.63 ± 7.71
9.68 ± 11.79

(n = 56)
67.07 ± 11.27
76.8 (43)
25.68 ± 5.15
15.95 ± 29.57

16.6 (13)

13.6 (3)

17.9 (10)

26.9 (21)
20.5 (16)
6.4 (5)
29.5 (23)
69.2 (54)
20.63 ± 12.45

18.2 (4)
27.3 (6)
4.5 (1)
36.4 (8)
77.3 (17)
24.71 ± 13.66

30.3 (17)
17.9 (10)
7.1 (4)
26.8 (15)
66.1 (37)
18.66 ± 11.5

65.4 (51)

63.6 (14)

66.1 (37)

62.8 (49)
114.13 ± 18.66
31.29 ± 5.69

72.7 (16)
109.50 ± 21.09
30.33 ± 6.19

58.9 (33)
115.98 ± 17.46
31.69 ± 5.48

(n=67)

(n=19)

(n=48)

55.2 (37)

47.4 (9)

58.3(28)

32.8 (22)

26.3 (5)

35.4(17)

13.4 (9)

10.5 (2)

14.6 (7)

29.9 (20)

26.3 (5)

31.3 (15)

dp
pt
dp
17.9(12) 16.4(11) 15.8(3)

pt
15.8(3)

dp
18.8(9)

pt
16.1(8)

Unless otherwise stated, values expressed as mean ± Standard Deviation with range in parentheses, or percentage (n).
Abbreviations: BMI = Body Mass Index; dp = Dorsalis Pedis; pt = Posterior Tibial
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Representative of the population, patients were predominantly male and the mean age
was 65.76 (range 28-90) years. Wound presentations were typical of a vasculopathic
population, and included chronic ulcerations, non-healing surgical sites and open
amputation wounds with underlying arterial, venous, diabetic or combined etiology. The
mean wound duration was 14.13 ± 25.8 months (as recorded in 76 out of 78 patients).
Most patients were taking an anti-coagulant medication and the majority were prescribed
antibiotic therapy. Many patients had long term diabetes and were insulin dependent.
Two patients could not recall the time since diabetes diagnosis, and this information was
not available from the medical record. As might be anticipated with a vasculopathic
population, 28% of foot wounds were not associated with diabetes, and 33.3% of wounds
of patients with diabetes were not on the foot.

ABPI was not obtainable in many patients mainly because of incompressible arteries. The
low inclusion threshold of 0.3 may not be suitable for debridement in usual
circumstances, but since subjects were evaluated by the vascular surgeon, was chosen to
ensure no patients amenable to wound response were excluded. Interestingly, although
the ABPI cut-off was 0.3, the 29 patients who were able to have the test had a mean
ABPI of greater than 0.9, which is defined as the threshold of peripheral arterial
disease.10 As expected, these normal ABPI results were reflective of the post
revascularization status rather than degree of vascular disease as 67 out of 78 (85.9%)
patients had clear evidence of arterial pathology. This included patients with previous
lower extremity bypass graft, angioplasty or amputations. Fifty-seven of 68 people in the
study had no palpable pedal pulse.

2.4.1

Individual Signs of Infection

The True Positive (TP), True Negative (TN), False Positive (FP) and False Negative (FN)
results with the sensitivity and specificity of individual clinical signs are presented in
Table 4. The most frequent sign was edema, which was present in 55 patients. Seventeen
(55%) patients with edema had a wound infection. Many patients in this study also had
delayed healing (n = 53 patients), debris (n = 52), and friable granulation tissue (n = 51).
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Notably, signs that were rarely seen in this population included induration (n = 2), wound
breakdown (n = 4), increased wound size (n = 4), and odour (n = 6). The two clinical
signs with the highest sensitivity scores were the presence of edema (0.77) and delayed
healing (0.73). Most other signs had moderate to low sensitivity which means that many
people, who were considered to have an infection, lacked these individual signs.
Table 4 Sensitivity and Specificity of Individual Clinical Signs
Sign
Heat

TP
6

FN
16

TN
51

FP
5

SENS SPEC
0.27
0.91

Increasing Pain

5

17

39

17

0.23

0.70

Erythema

12

10

44

12

0.55

0.82

Edema

17

5

18

38

0.77

0.32

*Edema/Erythema 11

11

48

8

0.50

0.86

Purulent exudate

3

19

50

6

0.14

0.89

Increasing wound
Size
Delayed healing

2

20

54

2

0.09

0.96

16

6

19

37

0.73

0.34

Wound
breakdown
Odour

3

19

55

1

0.14

0.98

3

19

53

3

0.14

0.95

Serous exudate

4

18

51

5

0.18

0.91

Debris

14

8

18

38

0.64

0.32

Friable
granulation
Induration

15

7

20

36

0.68

0.36

2

20

56

0

0.09

1.00

OR (95% CI)
3.83 (1.03 –
14.22)
0.68 (0.21 –
2.13)
4.40 (1.53 –
12.63)
1.61 (0.51 –
5.06)
6.00 (1.95 –
18.42)
1.32 (0.30 –
5.80)
2.70 (0.36 –
20.48)
1.36 (0.46 –
4.07)
8.68 (0.85 –
88.59)
2.79 (0.52 –
15.03)
2.27 (0.54 –
9.38)
0.83 (0.30 –
2.33)
1.19 (0.42 –
3.40)
3.80 (2.61 –
5.54)

LR+
3.0
0.8
3.1
1.1
3.6
1.3
2.3
1.1
7.0
2.8
2.0
0.9
1.1
nc

*Woo and Sibbald reported edema and erythema combined, not individually reported.
Abbreviations: TP = True Positive; FN = False Negative; TN = True Negative; FP = False Positive; Sens = Sensitivity;
Spec = Specificity; OR (95% CI) = Odds ratio with 95% confidence interval in parentheses; LR+ = Positive Likelihood
Ratio.
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Many signs showed relatively high (greater than 0.90) specificity. Heat, increasing
wound size, wound breakdown, odour, and serous exudate were not present in noninfected wounds over 90% of the time. As such, the absence of one of these signs was
viewed as highly suggestive that a wound infection was not present. Induration was not
seen in non-infected wounds at all. Further, several signs occurred in the absence of
bacterial growth (e.g. delayed healing, friable tissue, and debris), and therefore were
poorly specific for infection in wounds. That is, the signs that occurred for reasons other
than bacterial growth could not be used to identify an infected wound.
The odds ratio (OR) with 95% confidence interval (CI) for each sign is reported in Table
4. The 95% CI reveals that a large possible range of OR exists for most signs and
therefore the estimate is yet imprecise. Induration produced the most precisely elevated
OR at 3.8 (2.61 – 5.54, 95% CI). This means that considering the 95% CI, the true odds
of having an infection when induration is present is elevated by 2.6 and 5.5 times.
Interestingly, the odds of having infection crossed the “no difference” threshold (OR = 1)
of one for a sign that was previously thought to be important (increased pain). In fact, the
OR of most individual signs included CI’s that included the number one. Collectively, the
odds ratios did not suggest that the presence of any individual sign was strongly
associated with wound infection.
Wound breakdown produced the highest positive likelihood ratio (LR+) of seven. Pre-test
probability of infection was estimated at 31%,22 which means 79% of patients with
wound breakdown were likely to have an infection. All other individual signs had a LR+
of < 5 which has a small effect on the post-test probability. Unfortunately, negative
likelihood ratios (LR-) for individual signs were all above 0.2 (between 0.5 – 1.36),
which means the absence of any one of these signs does not necessarily mean the wound
is free of infection.

2.4.2

Comparison to Previously Validated Signs

Table 5 presents values for sensitivity and specificity in cases where the infection was
confirmed by a combination of the clinical diagnosis by the ID physician and the tissue
culture results, which were expressed semi-quantitatively. Our results (Murphy et al,
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2015) are compared to previous studies performed by Gardner and colleagues23, who
defined infection by yielding bacterial counts greater than 106 per gram of tissue, and
Woo and Sibbald,24 who identified moderate to heavy bacterial growth in cultured wound
fluid collected by wound swab using Levine’s method.15 As noted in Table 5, the values
for sensitivity and specificity discovered in this study are quite different than those
reported previously. We found several signs were more specific than previously reported,
but the sensitivity of signs examined by Woo and Sibbald24 were not attained. Along the
same lines as Gardner and colleagues,23 our study found most signs had better specificity
that sensitivity. That said, the few signs that they marked as sensitive were not the same
ones that we found to be sensitive in our study. This is important since it shows that
wound infections of people with vascular disease may fail to show signs of infection that
are typically used for screening in other populations.
Table 5 Sensitivity and Specificity in Current and Previously Published Studies

Sign
Heat
Increasing Pain
Erythema
Edema
*Edema/Erythema
Purulent exudate
Increasing wound
Size
Delayed healing
Wound breakdown
Odour
Serous exudate
Debris
Friable granulation
Induration

Murphy et al
2015

Gardner et al23
2009

Woo & Sibbald24
2009

n = 78
SENS
SPEC
0.27
0.91
0.23
0.70
0.55
0.82
0.77
0.32
0.50
0.86
0.14
0.89
0.09
0.96

n = 64
SENS
SPEC
0.12
0.85
0.12
1.00
0.32
0.77
0.20
0.77
0.26
0.65
-

n = 112
SENS
SPEC
0.76
0.71
*
*
*
*
0.87
0.44
0.70
0.64
0.50
0.83

0.73
0.14
0.14
0.18
0.64
0.68
0.09

0.34
0.98
0.95
0.91
0.32
0.36
1.00

0.48
0.20
0.88
0.00
-

0.54
0.87
0.21
0.77
-

0.37
-

0.86
-

*Woo and Sibbald reported edema and erythema combined, not individually reported. Some other items not reported in
published articles. Abbreviations: MD = Doctor of Medicine; SQ = Semi-Quantitive; Q = Quantitive; Sens =
Sensitivity; Spec = Specificity.
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Woo and Sibbald24 found different values for sensitivity than those derived from the
current study. In particular, they found the presence of both erythema and edema together
were highly sensitive to the presence of infection in the wound (0.87). That said, these
signs were not very specific. Our results were the opposite in that most people who did
not exhibit either of these clinical signs did not have infection. In other words, we found
the combination of these signs was more specific, and so their combined absence was
indicative of a non-infected wound.

2.4.3

Composite Signs

We combined two or more clinical signs (as defined by Woo and Sibbald24 and the
IDSA13 previously) to obtain the NERDS, STONEES, UPPER, LOWER and IDSA
values for sensitivity, specificity and likelihood ratios of these composite scores (as
presented in Table 6). A dummy code variable was used for calculations based on the
threshold of 2, 3 and 4 signs. Adding the number of individual signs together produced a
better balance between specificity and sensitivity with the combination of three clinical
signs included in STONEES and LOWER scales producing a rather high LR+ (greater
than 7.0). Despite this finding, we did not achieve the relatively high sensitivity and
specificity in any one sign found by Woo and Sibbald. That said, combining the clinical
signs defined by IDSA produced moderate sensitivity and good specificity. Our
specificity results (0.91) were stronger than those reported previously by Gardner and
colleagues,23 who had specificity results of 0.46. However, sensitivity was not improved
with the IDSA combination of signs which suggests using composite signs may not be
suitable as a screening method for patients with vascular disease, since these signs are
often absent in infected wounds.
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Table 6 Composite Signs of Infection in Current and Previous Studies: Sensitivity, Specificity,
and Likelihood Ratios

Sign

Woo & Sibbald24 2009
ID MD + Culture
SENS
SPEC
LR+

Murphy et al 2015:
ID MD + Culture
SENS
SPEC
LR+

IDSA signs

-

-

-

0.41

0.91

4.55

NERDS (2)
NERDS (3)
NERDS (4)

0.85
0.73
0.38

0.33
0.81
1.00

1.27
3.84
nc

0.83
0.31
0.11

0.23
0.54
0.69

1.08
0.67
0.35

STONEES (2)
STONEES (3)
STONEES (4)

0.95
0.90
0.53

0.50
0.69
0.92

1.9
2.9
6.6

0.59
0.36
0.14

0.82
0.95
0.98

3.28
7.2
7.0

0.83
0.43
0.22

0.23
0.46
0.69

1.08
0.80
0.71

UPPER (2)
UPPER (3)
UPPER (4)
LOWER (2)
LOWER (3)

-

-

-

0.59

0.80

2.95

-

-

-

0.36

0.95

7.2

Abbreviations: Sens = Sensitivity; Spec = Specificity; LR+ = Positive Likelihood Ratio; IDSA = Infectious Diseases
Society of America; NERDS = Composite infection tool (Non-healing, Exudate, Red friable tissue, Debris, Smell);
STONEES = Composite infection tool (Size bigger, Temperature increased, Osseous tissue, New areas of breakdown,
Erythema and Edema combined, Smell)30; UPPER = Composite infection tool (Unhealthy granulation tissue, Pain,
Poor healing, Exudate, Reek) and LOWER = Composite infection tool (Larger in size, Osseous tissue, Warmth, Edema,
Redness)31. Murphy et al = current study. Composite tools described with (2) = 2 signs present, (3) = 3 signs present;
(4) = 4 signs present. nc = Not Calculable. IDSA, STONEES and LOWER compared against ≥moderate to heavy semiquantitative growth; NERDS AND UPPER compared against < moderate culture growth.
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2.5

Discussion

The purpose of this study was to examine the validity of classical and subtle signs of
wound infection in patients with extensive peripheral vascular disease, who often require
surgical intervention. We have shown that several individual signs are specific for wound
infection in a vasculopathic population. Our study found most signs are poorly sensitive
which means when infection is present, clinicians cannot be confident these clinical signs
will appear. Yet when infection is absent, the presence of these signs rarely occurs. Since
there is poor balance between sensitivity and specificity, clinical signs alone are not a
suitable diagnostic test for wound infection in vascular patients.
Recent studies have used different criteria to define wound infection.22-24 Following
Gardner and colleagues, we used a tissue biopsy as the sample for culture. However, we
were unable to use a quantitative culture method to define an infection threshold. Like
Woo and Sibbald, we used a semi-quantitative scale. However, their samples were
obtained by culturing wound fluid, collected using the Levine method, which invariably
represents bacteria from more superficial layers. Using this approach, Woo and Sibbald
have quite a high rate of samples that cultured a light amount of bacteria.24
In order to provide the greatest diagnostic value, a balance between strong positive values
of specificity and sensitivity is required. In our study, the best balance between
specificity and sensitivity was obtained when several signs were combined. In particular,
the presence of three or four signs associated with previously defined STONEES yielded
positive likelihood ratios of greater than 7.0, which is considered clinically important.26
Confirming the results of Woo and Sibbald,24 our findings suggest a composite is more
informative in detecting infection than individual signs.
The different clinical signs observed in this study occurred non-uniformly. There were a
few signs that were seldom observed including induration, elevated peri-ulcer
temperature, odour and exudate. This finding was expected as the majority of patients
had diabetes and peripheral vascular disease, which is known to blunt inflammatory
response.32 There were a few signs that were commonly seen in our patients, including:
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edema, delayed healing, and fragile granulation tissue. A high false positive rate with
these signs is likely due to the characteristics of the patients under study.
The inability to achieve a 20% to 40% decrease in wound size within four weeks (defined
as delayed healing) was often associated with infection (True Positive = 16). That said,
delayed healing was also common in patients without infection (False Positive = 37). It
might be expected that delayed healing may occur in a population with vasculopathy
given the impoverished wound environment. Additionally, the high prevalence of friable
granulation tissue in the wound base may have occurred since 65.4% of patients in the
study took anticoagulant medication which is a common treatment for a vascular
population
Given that elevated wound temperature depends largely on perfusion, the infrequency of
this finding was expected. In this study, we detected elevated wound temperature using
slightly different techniques than previously.24 We opted not to compare temperatures to
the same location on the contralateral limb since limb temperature is affected by
perfusion and several of our patients had undergone unilateral vascular surgery or
angioplasty. Instead, we used the same infrared thermometry method to detect wound
temperature that was three degrees higher than the surrounding skin located 10cm distally
on the same limb. Using this approach, we found heat to informative since it was highly
specific (0.91), but poorly sensitive (0.27) as it was an infrequent finding.
We found, as Gardner, and colleagues23 did, that no single sign was strongly associated
with the presence of infection. Additionally, we did not find that increasing pain or
wound breakdown to be 100% specific. This may be because patients with arterial
disease were excluded from that study, since pain and wound breakdown may be
associated with ischemia.33 Contrary to their research, our study found increased pain was
only moderately specific for infection. That said, we also found that presence of pain did
not necessarily suggest infection was present. This difference may be because patients
with vasculopathy include those with diminished and altered pain experiences often
complicated by ischemia, edema and/or neuropathy.34 It is therefore expected that
vascular disease influences pain response with and without the presence of infection. The
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addition of a debridement procedure may have promoted anticipation of pain which may
have further muted this sign.
We found a composite of signs for infection to be more specific for our population than
in the two previous studies. Conversely, we did not confirm previous findings that
suggested certain signs including non-healing, exudate increase, friability, debris in the
wound and odour, to be associated with the presence of localized, superficial critical
colonization.24 This previous study showed more signs with a stronger sensitivity for
infection than our study. When comparing values for the positive likelihood ratio, we
confirmed the results of Woo and Sibbald, showing STONEES and LOWER with three
signs performed best as a specific measure of infection. That said, we did not find the
NERDS or UPPER composites achieved likelihood ratios that were informative when
compared with less than moderate culture growth. It is possible that our deeper tissue
culture method affected the results of the superficial bacterial burden assessment.
Although previous studies have focused on non-arterial populations, the ABPI inclusion
criterion is frequently 0.5, which is within current definitions of peripheral arterial
disease.10 Interestingly, Gardner and colleagues had defined arterial insufficiency as
being ABPI <0.5.22 Our population has a mean ABPI of around 0.90 but had a strong
representation of peripheral vascular procedures. It may be useful for future studies to
report previous vascular surgical history in addition to ABPI in order to gain an improved
sense of arterial pathology.

2.5.1

Limitations

Patients with PVD are known to be at very high risk of wound infection, and often
require hospital admission for vascular surgery and even amputation. However, the
incidence of bacterial invasion into the tissue biopsies taken in this study was fairly low.
The high standard of care provided by an experienced interprofessional team working at a
tertiary care hospital may have blunted our chances of determining whether clinical signs
are very sensitive at detecting new or emerging infections.
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Clinical signs recorded in this study were recorded by a single assessor who was the ET
RN. While specific criteria were used for each sign, these findings were not confirmed by
a second assessor and no test of reliability of the results produced by this assessor was
conducted. Furthermore, some criteria used to detect the presence of certain clinical
signs, previously defined by other groups (e.g. increased temperature) had to be modified
to fit this population. It is therefore very possible some signs of infection were missed or
mislabeled. However, using a highly trained nurse who has several years’ experience
with this patient population is advantageous in that this is the type of clinician who would
most benefit from a valid diagnostic test that is both sensitive and specific to infection in
this high risk population.
In our study, the culture results were combined with a clinical diagnosis of infection by
an ID physician. Therefore, the methods used to confirm the presence of infection were
not the same as in the described previous studies which used culture alone, not the
medical professional’s evaluation as the reference standard. In those studies, the
sensitivity, specificity and LRs of individual and composite signs were only calculated
against positive culture results. In our study, there was no increase in the sensitivity
and/or the specificity of individual signs when compared to culture alone. Additionally,
composite signs had reduced LR+s when compared to culture result alone. We also
compared clinical signs to culture results from a sample of tissue taken after extensive
wound debridement. As such, the tissue samples used represent a deeper layer of the
wound than surface swabs, which may have contributed to a lower rate of moderate to
heavy growth of bacteria. By combining these methods, we are confident that we
accurately assigned patients to either the infected or not infected groups.
We used a consecutive convenience sampling method for a patient group that was
serviced by a group of vascular surgeons. As a result, the patient group included in this
study was quite varied and included a subgroup of people with a long history of diabetes.
Several patients had recently undergone angioplasty and/or bypass grafting and some had
a wound at an unhealed amputation site. Furthermore, only 75% of those attending the
vascular service either consented or were eligible to participate in the study. Whether or

32

not these results can be generalized to all patients with peripheral vascular disease is
unknown.
We specifically excluded those patients that had immunosuppressive or palliative
conditions that could prevent healing, bleeding disorders, malignancy in the region or
excessive pain. Therefore, our results may not pertain to patients with these conditions.
The results of this study were also influenced by the assessment practices and standards
of the health care team managing these patients. For example, the physicians and
surgeons prescribed anti-coagulant and antibacterial medication in 65% and 63% of
patients, respectively. While these medications are considered limb saving by this health
care team, they invariably affect our results. Certain clinical signs such as induration
were not seen at all, and other signs (e.g., friable granulation tissue) occurred in most
patients regardless of whether infection was present.
The use of topical and systemic antimicrobials in the study may have reduced the
appearance of subtle signs of infection and resulted in a relatively small sample of
patients with overt infection. One previous group excluded patients on systemic
antibiotics when examining the change in clinical signs of infection. This exclusion was
due to concern that the host response would be affected by the medication, lessening
clinical signs.31 Given that our patient population had a very high requirement for
antibiotic therapy, excluding patients who were on antibiotics would have prevented us
from conducting this study.
The exclusion of patients with exposed bone limited the number of possible signs to
select that have formerly be noted to be indicative of deep infection in other populations.
It is therefore unknown if the addition of probe to bone sign would improve sensitivity or
specificity of the composite tools.24

2.6

Conclusion

Based on the results of this study there is a strong likelihood infection exists when three
or four signs associated with deeper infection (e.g., wound breakdown, increasing wound
size, odour, heat, serous exudate) are present. Importantly, we have also found that the
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presence of any of one or more clinical signs cannot be used to confirm that an infection
exists. As a part of this study, we found signs of superficial infection or critical
colonization were not strongly associated with a smaller growth of bacteria or the
subclinical diagnosis of infection. These results are influenced by the specific
characteristics of the vasculopathic patient group tested, the rigorous method of the ID
physician used to confirm the presence of infection, and the subjective nature of detecting
clinical signs.

2.6.1

Clinical Implications and Future Research

Our results suggest that it is not suitable to use clinical signs of infection as a screening
method, when determining the presence of infection for patients with vascular disease.
Although certain signs of infection may occur, they may be a late and unreliable
indication of infection.
Importantly, in light of the drive to reduce unnecessary antibiotic prescriptions, wound
infection may fail to overtly present in this vulnerable population. Notably, the findings
of this study show that most signs are less likely to be present in a population with
vasculopathy. In our analysis, many signs that were more frequently seen when infection
was present were also noted when infection was absent, and so were of little clinical
value. Therefore, if the wound is not healing at a reasonable rate and without
complications, it may be prudent to have a low threshold to send a sample for bacterial
analysis.
Validating a clinical tool to identify infection for people with PVD and poor healing
potential is important since little is known about this population often excluded from
clinical trials. Further, determining a group of clinical signs that represent a very high
likelihood of wound infection in PVD patients is critical since wound infection can have
grave consequences including amputation and even death. Our study found that no sign
either individually or in combination was sensitive enough to detect infection, which
means visual inspection of a wound cannot be used to rule out infection. Therefore, the
use of both tissue biopsy and clinical exam by an ID physician may be warranted to
screen this patient group for infection.

34

There is urgent need for future research to develop more objective point-of-care
diagnostic tests for wound infection in the vascular population as well as for other
groups. Additionally, future research using newer precise genetic methods of bacterial
identification as the gold standard is warranted. Future studies are also needed to address
the challenges of this population, and to better understand assessment and management
practices.
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Chapter 3: The UltraHeal Pilot study: Tolerability and
feasibility of 22.5 kHz low frequency contact ultrasound
debridement (LFCUD) for patients with lower extremity
wounds and vascular pathology

3

3.1

Introduction

There are few effective methods to support wound healing in patients with vascular
disease. Lower extremity wounds complicated by arterial and venous pathologies can be
extremely challenging to heal, and these non-healing wounds are associated with
recurrent infections, limb amputation and death.1 Therefore, more effective methods are
needed to support healing in this vulnerable population. One approach is to improve the
quality of, and access to, debridement procedures. These procedures improve the wound
environment and are an essential part of preparing the wound for healing.2-4 Despite the
need for this step in wound preparation, debridement is not consistently available for
these patients. A method of ultrasound debridement that might be safely and comfortably
administered in a nurse-led wound clinic is intriguing as it may improve access to care
and possibly improve outcomes.

3.1.1

Peripheral Vascular Disease

Peripheral vascular disease (PVD), which is associated with the development of lower
extremity wounds is an increasingly prevalent health problem.5 PVD includes similar,
yet not equivalent, forms of blood vessel pathology such as peripheral arterial disease
(PAD), peripheral arterial occlusive disease, venous insufficiency, and lower extremity
arterial disease (LEAD). All of these conditions affect blood flow within the lower
extremities. While the prevalence of these various vascular pathologies is difficult to
determine since many patients are asymptomatic, the prevalence of LEAD is thought to
be increasing. LEAD is linked to increased age and other conditions of growing
prevalence including diabetes, hypertension, dyslipidemia, and chronic renal failure.5 It
has been estimated that LEAD is present in 30% of the population over 70 years of age,6
and 40 % of the population over 80 years.7 Poor arterial blood supply is the hallmark of
LEAD and can result in death of individual cells, which can lead to the development of
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lower extremity wounds. Therefore, the occurrence of non-healing wounds is often a
symptom of advancing LEAD. A recent Canadian study found the highest prevalence of
compromised wounds was found in patients with PVD, and in acute care settings,
patients with generalized cardiovascular disease had the highest wound prevalence.8
Patients receiving lower extremity revascularization procedures have readmission rates
three times higher when an open wound is present prior to vascular surgery.9 However,
vascular surgery is often critical for providing sufficient blood flow to permit healing to
occur.10 Patients with diabetes frequently have lower leg tibial vessel disease, which may
be suitable for arterial reconstruction procedures such as arterial bypass or angioplasty.11
Further, given that post-operative blood flow may be improved for an unknown period of
time, effective wound therapies such as LFCUD could be especially beneficial within a
limited window of opportunity.
A diagnosis of diabetes has been reported to increase the risk of LEAD by two to four
times, and to increase compromised wound prevalence by almost six times.8 Since
diabetes is now considered a global pandemic, it is predicted that the incidence of LEADrelated wounds will continue to escalate.12 Wounds that are related to soft tissue
infections and osteomyelitis are responsible for around 25% of all hospital admissions for
persons with diabetes.8 Responding to this growing need for effective wound therapies in
a vulnerable population, this study evaluates a therapy that might improve wound
outcomes. We examined if offering more aggressive and targeted wound therapy in the
outpatient setting could potentially reduce some vascular and diabetes-related acute care
admissions, days of in-hospital stay and associated costs.

3.1.2

Debridement

The procedure of debridement involves the removal of non-viable material, foreign
bodies and poorly healing tissue from a wound.13 Debridement that activates a bleeding
response usually involves cutting away the dead tissue with a scalpel and attempting to
avoid damage to the healthy cells. Although higher rates of wound closure are associated
with an increased frequency of debridement episodes,14 there is a requirement for
particular clinical skills and often a surgical environment to offer sufficiently thorough
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debridement to affect wound progress. Clinicians are often apprehensive about
performing aggressive debridement on patients with vascular disease because of the risk
of causing further tissue damage. Additionally, patients are often anti-coagulated and
may bleed excessively. Sharp debridement may enlarge the wound when there is limited
ability to heal since determination of the edge between healthy and unhealthy tissue is
visual and imprecise. This study investigates if low frequency contact ultrasound
debridement (LFCUD), a form of debridement that selectively targets dead tissue whilst
providing a stimulant effect of ultrasound energy, may offer a solution to this dilemma.

3.1.3

Ultrasound

Ultrasound is defined as acoustic energy which is above the level of human hearing
(greater than 20 kHz).15 It has been used for various therapeutic applications since
around 1950,16 and is considered to be a safe, effective and relatively easy to use mode
of wound therapy with few adverse effects.17 Ultrasound energy is used in many
dissimilar therapeutic devices, which encompass a wide range of frequencies and
transmission methods. Different devices have potentially variable degrees of biological
effect including tissue response18, 19 and antibacterial properties.20-22 Ultrasound
frequency (f) is measured in Hertz (Hz) which are units that describe the number of times
a molecule subjected to ultrasound is displaced and recovers in cycles per second.
Variations of frequency are known to affect the depth of tissue penetration, cellular
response, heat generation and dispersal of ultrasound into superficial tissue (known as
attenuation).16
The frequency range of LFCUD devices spans from 22.5 kHz to 35 kHz, and this range is
known as long wave or low frequency ultrasound.15 Differences in the amount of
ultrasound delivered and the tissue response will occur depending on the probe design, on
the ultrasound intensity (measured in Watts per centimetre squared), on the treatment
duration, and on whether or not the device is in pulsed or continuous mode. For an indepth review of a variety of ultrasound therapies, see Kloth and Niezgoda.15
Several clinical reports have documented the beneficial effects of a combined ultrasound
and debridement system, similar to the treatment used in the current study, in different
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populations.17, 23, 24 These reports have found 25 kHz LFCUD to be well tolerated in a
diverse group of patients suffering from a variety of chronic non-healing wounds. The
focus of this paper is the effect of the lowest frequency device (22.5 kHz) ultrasound that
involves direct contact of the probe to the base of the wound.

3.2

Research Purpose

Patients in the vascular surgery wound clinic are a vulnerable population, who frequently
have a high frequency of wound complications including infection, accumulating necrotic
debris, poor granulation response and slow or absent wound closure. The purpose of this
pilot study is to determine the tolerability and feasibility of using 22.5 kHz LFCUD in a
nurse-led vascular surgery wound clinic. The anticipated goal of LFCUD treatments is to
reduce complications and improve clinical outcomes among patients with vascular
insufficiency, who may also have diabetic neuropathy and/or wound infection. This study
examines whether or not LFCUD, a selective method of debridement, stimulates wound
healing, impacts wound size or improves wound appearance. The following research
questions guide the study:
1) Is there a reduction in wound size after four weekly LFCUD treatments plus
usual care? If so, by what amount?
2) Is there an improvement in wound appearance after four weekly LFCUD
treatments as determined by validated assessment tool (revPWAT)?
3) Is LFCUD well tolerated? Are there minimal adverse reactions that are unrelated
and related to treatment?
4) Is LFCUD feasible to apply in a nurse-led vascular surgery wound clinic?

3.3

Methods

This prospective single arm observational study compared wound appearance and size
before and after a series of four weekly 22.5 kHz LFCUD treatments (see Figure 1). A
consecutive sample of patients with lower extremity wounds, who were referred from an
acute care vascular service, were recruited. Wound assessments were completed at a
baseline visit (Week 0) as well as one week after the last ultrasound treatment (Week 5).
Patients also returned for follow up visit at Week 12. This study involved: (1) securing
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approval from the university and hospital Research Ethics Boards (REBs); (2) recruiting
patients; (3) administering treatments (e.g., usual care, negative pressure wound therapy,
initial debridement, LFCUD); (4) evaluating patients (e.g., for wound size, wound
appearance, pain, skin grafting, adverse events); and, lastly (5) analyzing the data.
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Figure 1 Study flow diagram
Screening
Screen Form (ET RN)
Vascular Assessment
Recruitment
Pre-treatment(Week 0 - Baseline visit )
Infection Assessment (ID)
Pain (VAS)
WSA (Planimetry)
Wound Appearance (revPWAT)
Week 1 - LFCUD Treatment 1
WSA
Pain Pre and Post Treatment
Adverse Events
Week 2 - LFCUD Treatment 2
WSA
Pain Pre and Post Treatment
Adverse Events
Week 3 - LFCUD Treatment 3
WSA
Pain Pre and Post Treatment
Adverse Events
Week 4 -LFCUD Treatment 4
WSA
Pain Pre and Post Treatment
Adverse Events
Week 5 - Post-treatment
Infection Assessment (ID)
Pain (VAS)
WSA (Planimetry)
Wound Appearance (revPWAT)

Week 12 - Follow-up visit
Wound Closure
Pain (VAS)
WSA (Planimetry)
Complications
Hospital Visits Pain (VAS)
WSA (Planimetry)

Abbreviations: ET RN = Enterostomal Registered Therapy Nurse; ID = Infectious Diseases physician; VAS = Visual
Analogue Scale; revPWAT = revised photographic wound assessment tool; LFCUD = low frequency ultrasound
debridement; WSA = wound surface area
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3.3.1

Study Approvals

The methodological quality and study protocol was reviewed and approved by both the
university and clinical Research Ethics Boards (see Appendices 1 and 2), and was
monitored by an external Data Safety Monitoring Board. Further, the Vascular Surgery
Department designed and activated a Medical Directive, and implemented a Delegated
Medical Act to ensure that all appropriate permissions and skill competencies were
reviewed and approved by the Nursing Professional Practice Department and the
Department of Vascular Surgery.
Training on the Sonic One® device was provided and certification was awarded to the
Enterostomal Therapy Nurse (ET RN) on the ultrasound debridement technique by the
manufacturer (Misonix, Farmingdale, USA). This training was conducted in coordination
with the Program Director of Vascular Surgery at the study centre.

3.3.2

Patient Recruitment

Patients were recruited to represent a typical and varied population that receives wound
care from a vascular surgery department. Patients who had a lower extremity wound, and
were either attending the hospital outpatient vascular surgery clinic or admitted to the
vascular surgery in-patient unit, were approached by one of six vascular surgeons or their
delegates during their routine clinic or hospital visit. Subjects included were those with
treated infections, diabetes, peripheral vascular disease, neuropathy and various other
comorbidities. Patients were at least 18 years of age and were willing to commit to the
weekly treatment schedule. Additionally, patients were eligible if they had a lower
extremity wound greater than 1cm2 wound surface area (WSA), had ankle brachial
pressure index (ABPI) of greater than 0.3 and did not have a vascular intervention
planned (or deemed necessary) in the upcoming weeks. Patients were excluded if they
had any conditions that could be aggravated by LFCUD (e.g., acute deep vein thrombosis
or acute coagulopathy, malignancy in the region of therapy, or excessive pain). Patients
with pacemakers or internal cardiac defibrillator devices were also excluded since it was
not feasible to verify with all possible manufacturers that these devices would not be
compromised. We also excluded patients if they had untreated infections, exposed
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vascular graft or bone, were immunosuppressed, medically unstable or unlikely to
complete the study. Patients with severe arterial insufficiency that was likely to prevent
healing (i.e. pre-operative or palliative status as determined by the vascular surgeon) were
excluded from the study.
Patients who agreed to be contacted were then approached by the researcher. The study
was explained and an approved letter of information was provided in plain language that
described the study protocol and all risks. Patients were asked to take the information
home and consider the information for at least 24 hours. Those who elected to participate
then contacted the administrative assistant to arrange the first visit. Each patient was
assured that their choice regarding trial enrollment would not affect their access to
ongoing wound care.

3.3.3

Treatment

Ten patients were recruited to receive weekly 22.5 KHz LFCUD treatment over the
course of four weeks. The LFCUD was applied by the Enterostomal Therapy Registered
Nurse (ET RN) in the setting of an acute care vascular surgery wound clinic or in a
private room in the in-patient vascular surgery ward (see Plate 2). The LFCUD treatment
was applied until necrotic debris was removed and the wound surface was lightly
bleeding. Patients taking oral analgesic to manage the pain for dressing changes
continued to do so. If the patient suggested that the analgesia was insufficient, a local
lidocaine injection was offered as an anaesthetic. At each visit, patients were encouraged
tell the ET RN should they become uncomfortable during LFCUD treatment. Further, all
patients were advised that local anaesthetic was available and that treatments could be
stopped at any time upon their request.

3.3.4

Ongoing Usual Care

All patients in the study continued to receive ongoing wound care as is provided in the
vascular surgery wound clinic or ward. Typically, their treatment included moist wound
therapy, pressure offloading or compression wrap as warranted. Their treatment also
involved monitoring for infection as per the Clinical Infectious Diseases Practice
Guidelines.25, 26 Patients were provided with the same antimicrobial dressing (Silvercel,
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Acelity, San Antonio, Tx) or Negative Pressure Wound Therapy (NPWT) based on
wound characteristics. Patients with large, deep or structurally unstable wounds received
NPWT as this is a usual treatment method to support healing for this patient group.
NPWT was provided in one of two available formats: the Vacuum-Assisted Closure
Device (VAC®, Acelity, San Antonio, USA) and Renasys® (Smith and Nephew, London,
UK). The format was selected by the community nursing agency based on availability.
Both NPWT systems incorporated a foam layer that was directly placed on the wound
bed without an interface dressing. NPWT was achieved by placing an occlusive dressing
over the foam layer, and then attaching tubing to a negative pressure machine that creates
a gentle suction on the wound bed. Patients received intermittent NPWT therapy (five
minutes on and two minutes off) with the aim of promoting granulation response and
supporting local perfusion.

3.3.5

Initial Debridement

At the initial visit (at Week 0) an Infectious Diseases (ID) physician evaluated the patient
for wound infection and provided systemic antimicrobial therapy as needed. This
physician also provided an initial removal of all necrotic tissue using a standard sharp
debridement technique. This debridement ensured all patients had a standardized baseline
wound status. After cleansing with physiological saline solution, a tissue sample was
taken for a standard bacterial culture and antimicrobial susceptibility analysis. The
sample was immediately sent to a clinical laboratory for semi-quantitative bacterial
analysis in aerobic and anaerobic conditions. Regardless of whether or not necrotic debris
was visible, the wound bed was debrided to produce active bleeding.

3.3.6

Low Frequency Contact Ultrasound Debridement (LFCUD)

The Sonic One® (Misonix, Farmingdale, USA) device was used for all LFCUD
treatments (see Appendix 4). This device consists of a generator with an application
probe containing a piezoelectric crystal which converts electrical energy into mechanical
ultrasound energy as the crystal oscillates at 22,500 times per second. As a part of this
process, the rapid contraction and expansion of the crystal causes acoustic streaming and
cavitation. Streaming refers to micro currents that form in the saline irrigation couplant
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which occur in addition to a violent collapse of microbubbles (cavitation). By these
mechanisms, selective emulsification and removal of necrotic debris occurs, and viable
tissue remains intact until a clean, lightly bleeding wound surface is revealed (see
Appendix 5). The Sonic One® device maintains a constant intensity and frequency, and
delivers more or less energy depending on the type of tissue and force applied by the
clinician.
The Sonic One® device, which is operated with a pedal switch, was prepared for each use
with an autoclaved hand piece and removable probe with sterile disposable tubing set for
saline delivery. Personal protective equipment for aerosol generating procedure was
utilized during each treatment application (as per local infection control practices). Sterile
gloves were donned to handle the sterile components during treatment, and sterile touch
technique was used for all wound care and dressing applications (as per local clinical
practice). A pre-treatment and post-treatment wound rinse of 0.05% chlorhexidine was
provided with each treatment to remove any bacteria including those that may have been
released from a chronic biofilm during treatment.
In most instances, the LFCUD was applied with the standard gold probe (Figure 2). A
green probe (see Appendix 7) was selected if patients were apprehensive or concerned
about pain as it provides a more gentle application with wider ultrasound energy
dispersion. Ultrasound was applied in a continuous mode, which means there was no
interruption in ultrasound dosing during treatment. The probe was applied to the wound
bed at a setting of Amplitude 5, which is the maximum probe head movement setting (see
Appendix 6) and provides the most aggressive debridement. Physiological saline was
used as the coupling and cooling agent. The sterilized probe was placed in contact with
the wound bed and applied with a gentle circular motion to all areas of the wound
surface. This treatment continued until light bleeding was visible and no necrotic debris
remained. The time of application and type of probe type were recorded for each LFCUD
treatment. The mean treatment time was 3.5 minutes.
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Figure 2. A sample of Sonic One ® probes

From left to right: Blue probe (for deep tunneled areas); Gold probe (for regular use), front and side views; Magenta
probe (for adherent debris)

3.3.7

Evaluation

At each visit, the ET RN performed an overall wound assessment as is usual clinic
practice. The number of wounds that closed and re-opened were recorded, as well as the
incidence of wound-related pain and wound infection. Any complication, emergency
room or physician visit, or hospital admission that occurred during the 12 week
observation period was also documented. As a part of this clinical trial, the following
outcomes were evaluated: (1) wound size; (2) wound appearance; (3) wound pain; and
(4) adverse reactions. All study data were entered into a secure research database
(Empower Health Research, Inc.).

3.3.8

Wound Size

As a part of the evaluation, an independent assessor, who was a Registered Practical
Nurse (RPN), measured the wounds at each visit by tracing the wound edges onto an
acetate film, recording the planimetry data and entering these measurements into the
electronic database. The measurements were determined by the Visitrak® planimeter
(Smith & Nephew, London, UK), which is an instrument that has been previously shown
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to accurately determine WSA in centimeters squared.27 Each measurement was taken
three times with the mean of the three results recorded to reduce error of measurement.
Measurements were taken after the initial debridement to document the baseline WSA,
and before the LFCUD treatment at each weekly visit.

3.3.9

Wound Appearance

To measure wound appearance, the RPN took a photograph of the wound at each
appointment. The photography was taken using a Canon Rebel 300D EOS, 8 megapixel
resolution, 60mm macro lens digital camera with a ring flash, automatic focus and
consistent ambient lighting. This photograph was then used by the ET RN to score the
wound progress using a previously validated revised Photographic Wound Assessment
Tool (RevPWAT). The revPWAT is an eight item pen and paper tool that assigns a
decreasing numerical value to aspects of wound healing.28 With a maximum score of 32,
a decreasing score illustrates that a wound that is improving. Scoring of the photographs
was done with photos out of sequence so that the previous patient score was unknown.
The revPWAT tool allowed us to consider changes in wound size, depth, necrotic tissue
type/ amount, granulation tissue type/amount, wound edges, and periwound skin
viability.

3.3.10

Wound Pain

To measure wound pain, the RPN asked patients to rate their pain intensity before
LFCUD treatment using the previously validated Visual Analogue Scale (VAS). The
VAS uses millimetre increments with maximum pain possible at 100mm (VAS ruler,
Molnlycke, Gothenburg, Sweden).29 As a part of the evaluation, the RPN asked each
patient to move a marked plastic tab on the VAS ruler to indicate their wound pain level.
For each measurement, the RPN requested that the patient distinguish wound pain from
limb or other pain. The ET RN also asked patients to rate their pain after treatment and
recorded the number of patients who required local anaesthetic.
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3.3.11

Adverse Events

Adverse events were noted to be present or absent at each visit, and all adverse events
were reported to the Data Safety Monitoring Board following the requirements of the
REBs. The vascular surgeon and ID physician were notified with every concern, to
determine if any event was related to the treatment and if further medical care was
required. The number of major and distal lower extremity amputations as well as the
number of emergency room visits and related hospital admissions were also noted for the
duration of the study. All ten patients who received treatment were included in the
statistical analysis. One subject missed Week 5 due to transport issues, and another
subject missed the Week 12 follow up visit due to a scheduling error.

3.3.12

Skin Grafting

To ensure optimal patient care, patients were referred to the plastic surgery service as
soon as their wounds were granulating well and appeared appropriate for skin grafting
(regardless of whether or not the four LFCUD treatments had been completed). The
decision to close by grafting and the timing of the procedure was determined by the
plastic surgeon. Patients who were grafted received a split thickness skin graft (STSG)
retrieved from the anterior thigh or abdomen. The two patients who received STSGs were
receiving NPWT, and continued to receive NPWT for five uninterrupted days post graft
as is local usual procedure to support graft success.

3.3.13

Data Analysis

All data was collected and stored in a secure research database (EmPower Health
Research, Inc., London, Ontario, Canada), and analyzed using SPSS v.23 (SPSS, IBM
Corporation, Armonk, NY). All subjects completed the 12 week observation period,
however, one subject missed the final visit, and one subject had already received a STSG.
For conservative estimation, the last outcome carried forward was used to impute these
missing data. The change in wound surface area before and after the LFCUD treatment,
and between Week 0 (baseline) and Week 12 was calculated and compared using the
Paired Student’s t-Test. The mean percentage change in wound surface area was also
calculated. To determine the change in wound tissue quality before and after the
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treatment period (Week 0 and Week 5), the change in mean revPWAT score was
calculated and compared using the Paired Student’s t-Test. The mean value ± Standard
Deviation of the total revPWAT score was calculated before, and after LFCUD treatment
period (at Week 0 and Week 5). Given the relatively small sample size, data were tested
for normal distribution by a visual inspection of histogram and Shapiro-Wilks test to
verify that the parametric method was appropriate. Additionally, the revPWAT data was
subjected to a nonparametric analysis (Wilcoxian Rank Test) without a change in results.
Demographics and related medical information were also recorded. Mean values and
standard deviations were calculated for continuous variables (e.g. age, wound duration),
with frequency and range used to express dichotomous variables (e.g. gender, diabetes).

Results

3.4

Ten patients were recruited in the study from December 2013 until April 2014. Fourteen
consecutive patients were invited to participate in the study, but three subjects were found
to be ineligible at first debridement due to either depth of wound (n = 2), or untreated
osteomyelitis (n = 1). One subject was withdrawn just prior to starting LFCUD
treatments due to rapid decline in health status. Data are presented for the ten eligible
patients who participated in and completed the study.

3.4.1

Patient Demographics

Patient demographics are reported in Table 7. Eight of the ten patients were male. The
mean age of the participants was 66.1 years (SD = 9.9, range = 55-85 years). The average
mean duration of wound was ten months, and seven of the ten participants’ wounds were
located somewhere on the foot. Seven out of ten patients had advanced arterial disease,
two patients had painful venous leg ulcers of more than two years in duration, and one
patient had occluded micro vessels in the foot after a sepsis event. Seven patients had
diabetes with concurrent neuropathy and were being treated for infection. Three of the
patients had previous limb amputation including one major, one distal, and one distal
followed by major amputation procedure. Lastly, four patients had undergone previous
re-vascularization procedures (n = 4 angioplasty; n = 2 bypass procedure prior to
angioplasty).
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Table 7 Characteristics of Patients Enrolled in UltraHeal Pilot Study
Characteristic
Age (Years)
Sex (Male: Female)

M SD (range [-] or distribution
(n = 10)
66.1 ± 9.9 (55-85)
10 (8:2)

Wound Location:
Toe/ Toe amputation site
Foot (Plantar, Dorsal)
Heel
Leg
Wound Duration (months)
Initial Wound Surface Area (cm2)

2
3 (1,2)
2
3
10.1 ± 11.4 (2 – 36)
30.34 ± 26.2 (1.93 – 63.8)

Diabetes :
Neuropathy

7
7

Antibiotic therapy

7

Previous Lower Limb Amputation:
Distal only (pedal)
Major only (trans-femoral /trans-tibial)
Distal AND Major

3
1
1
1

Previous vascular intervention affected limb
Angioplasty
Bypass Graft:
(Angioplasty AND Bypass graft)

4
4
2
2

Abbreviations: cm2 = centimetres squared
Values expressed as frequency distribution or mean ± Standard Deviation with maximum and minimum values or
distribution in parentheses.
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3.4.2

Wound Size

The Wound Surface Area (WSA) significantly declined over the course of the treatment
(see Figure 3). In nine of ten cases, the wound size decreased progressively with weekly
treatments of low frequency ultrasound. The tenth person had unchanged wound surface
but it was later suspected that there may have been repetitive trauma occurrences from a
wheelchair foot rest with transfers. The initial mean WSA was 30.35cm2. After four
LFCUD treatments, the mean decrease in WSA observed over six weeks was 15.52 cm2
(2.73-28.32cm2 95% CI), which was statistically significant (p=0.023). The average
percentage area reduction during this treatment period was 39.4% (SD ± 29.3). None of
the wounds enlarged. Wounds continued to decrease after LFCUD stopped but at a
slower rate. The total percentage WSA reduction from Week 5 to Week 12 was slower
than it had been during the treatment phase at 25.9%. One patient had a small re-opening
at Week 12 and it was later determined that a vascular graft occlusion had occurred. This
wound was also colonized with Pseudomonas Aeruginosa and despite these barriers, we
were pleased to note that the wound later achieved closure with a successful skin graft.
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Figure 3 Change in wound surface area by planimetry from baseline (week 0) to posttreatments (week 5), and at 12 week follow-up visit

Mean WSA % change:

*

Baseline
(Week 0)

Post-treatment
(Week 5)

Week 1 – 6 = 39.4% (SD ± 29.3)
Week 1 – 12 = 65.3% (SD ± 32.1)

Follow-up
(Week 12)

Error bars = ± 1 Standard Deviation (SD). Mean Wound Surface (WSA) area measured using acetate tracing and
planimetry at baseline (Week 0), and after 4 weekly LFCUD treatments (Week 5). The follow up visit (Week 12) is
shown for comparison. Asterisk denotes statistical significance, (p = 0.023)

3.4.3

Wound Appearance

Wound appearance significantly improved from baseline following the weekly LFCUD
treatments (Figure 4). In nine of ten cases, the wound appearance improved progressively
with four weekly treatments of LFCUD. The tenth person had an unchanged wound
appearance, which, as previously mentioned, might be attributed to repetitive trauma
occurrences from the wheelchair foot rest with transfers. The mean revPWAT score
derived from digital images taken at baseline prior to commencing LFCUD treatment was
22.6 (SD ± 2.95). After treatments concluded (Week 5), there was a decrease in mean
revPWAT score of 8.3 out of the possible 32 points (SD ± 5.03, 4.7- 11.9 95% CI,
p=<0.01), indicating a significant improvement in wound appearance. This decrease in
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revPWAT score was primarily due to the improved appearance of healthy granulation
tissue. Eight out of ten wounds had lower revPWAT scores after LFCUD treatments,
suggesting they each demonstrated better tissue health. For the other two patients, one
had the missed visit and the other had been newly skin grafted, which meant the health of
the wound base could not be determined. In both cases, data were imputed using the last
outcome carried forward as a conservative measure.
Figure 4 Change in wound appearance by revPWAT score from baseline (week 0) to
post-treatments (week 5)

*

Baseline

Post-treatment

Error bars = ± 1 Standard Deviation (SD). Mean revPWAT Scores determined from digital images taken prior to
LFCUD (baseline), at baseline (Week 0), and after 4 weekly LFCUD treatments (Week 5). Asterisk denotes statistical
significance, (p= <0.01).

3.4.4

Wound Pain

Wound pain was found to decrease over the course of the weekly LFCUD treatments.
The mean decrease in VAS pain scores form Week 0 to Week 5 was 6mm (-6.7 to 18.7,
95% CI). No patients refused treatment based on concerns about pain, and all treatment
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sessions were attended. One patient required local anaesthetic at the first two visits, but
did not require it at the final two visits as the wound improved. Most patients who had
experience with sharp debridement commented that this form of debridement was much
more comfortable. Patients stated that the treatment sensation they experienced was more
of a vibration sensation than a painful stimulus, noting they were pleasantly surprised
with their treatment experience. In fact, pre-treatment and post treatment pain measures
demonstrated that LFCUD treatments were well tolerated and did not induce much
discomfort.

3.4.5

Adverse Reactions

There were no LFCUD treatment-related adverse reactions. Three patients suffered from
adverse events unrelated to the treatment. One patient reported a failure of his NPWT
device that had occurred for three days continuously prior to the visit. The device had
been left in place during the pump failure, and the patient presented with a new localized
wound infection. At the study visit, the patient was examined by the ID physician, and
antibiotics were prescribed with resolution. Successful skin grafting was performed the
following week as scheduled. A second patient was admitted to the hospital for
congestive heart failure and renal failure. This patient also suffered a rash that may have
been related to an antibiotic medication. An adjustment of medications was required, and
this patient was discharged after ten days. The wound continued to improve during this
period. A third patient, who had a proximal dorsal foot wound, incurred a toe infection on
the same foot. The toe required amputation and the infection resolved. A study team
meeting was called and all members agreed that the toe infection was not related to the
treatment since the infection was not near the treated area and the study wound had
continued to improve during this time. The Data Safety Monitoring Board was also
notified of these events as were the individual vascular surgeons who were overseeing
each case.

3.5

Discussion

This single-arm prospective pilot study has demonstrated for the first time that, in a
vascular clinic population, 22.5 kHz LFCUD is tolerable, feasible to apply, and unlikely
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to cause adverse events. We found that weekly LFCUD treatments could be provided as a
reasonable treatment schedule, and were easily incorporated into an out-patient wound
clinic setting. In this current study, in nine of ten cases, the wound appearance improved
and wound size decreased progressively with weekly treatments of LFCUD. For the
person with unchanged wound status, it was suspected that he may have suffered
repetitive trauma that may have affected his results.
We were particularly pleased to find that overall there was minimal pain with treatments.
While the patient who required local anaesthesia did find the treatment uncomfortable at
first, this was no longer the case at later sessions when local anaesthetic was administered
and when wound acuity decreased. Patients tolerated the procedures well, which has been
noted previously in one study, which found that 19 patients with recalcitrant venous leg
ulcers reported negligible pain that did not require local anaesthesia after an average of
five treatments administered every two to three weeks.24 Similarly, Herberger found
LFCUD was well tolerated compared to conventional surgical debridement procedures.17
This is an important point since pain may be a perceived barrier to debridement in some
clinical settings. The mean pain score declined between Week 0 to Week 5 (posttreatment visit) and tolerability of the treatment was also reflected in our 90% study
completion rate.
We had surmised that treatment might stimulate an initial healing response in this
challenging population, and were pleased to note a significant improvement in wound
appearance in this sample of patients. This result follows a previous study, which treated
17 patients with a variety of chronic wound presentations and found that 53% either
healed in eight months or similar to our population, had healthy granulation suitable
enough for skin grafting.30 We found 30% of our patients had wound appearance that
improved enough to be eligible for split thickness skin graft (STSG),(see Plates 3 and 4).
This is an important finding since patients in the vascular surgery wound clinic have high
incidence of poor quality granulation tissue and are therefore not commonly prime
candidates for STSG. One of these patients achieved a successful STSG despite having a
positive culture for Pseudomonas Aeruginosa, which is a bacterium known to contribute
to STSG failure.31
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Patients in this pilot study demonstrated a significant decrease in wound size. We did not
find this surprising, since several past studies have reported applications of ultrasound
energy to have a positive effect on wound healing.24,30 It is widely accepted that wounds
that fail to heal may be delayed in the inflammatory phase. It is possible that ultrasound
debridement assists conversion to the proliferative phase by stimulating growth factor
release. Growth factors are known to influence the growth of new blood vessels
(angiogenesis) needed to repair damaged tissue,32 and are a critical part of producing
healthy granulation tissue.33, 34 Debridement to bleeding acts as a trigger for growth factor
release since the blood clot material provides multiple growth factors as it degrades.34
Growth factors then summon fibroblast cells, which produce new collagen to provide
structure and strength to the new tissue. Ultrasound energy is known to boost the ability
of fibroblasts to produce collagen, and to stimulate new blood vessel growth to support
new granulation tissue.35 Ultrasound is also known to have a blood vessel dilation effect
which opens up blood flow to the wound.36 Therefore, LFCUD could provide several
enhanced attributes that may be beneficial to patients with vascular disease.
Several studies have investigated the effect of various types of ultrasound on wound
healing outcomes. These include indirect ultrasound applications through water or vapor,
and at higher frequencies (MHz). One study employing a 30 kHz foot bath was found to
significantly reduce venous leg ulcer areas at three and eight weeks compared to a control
group.37 Subsequently, a case-series study of 23 patients found 69% of patients with
chronic, previously non-healing lower extremity wounds were able to achieve healing
with 40 kHz ultrasound applied through a saline vapor. We were pleased to find a 39.4%
WSA decrease over four weeks in a challenging population, since this rate is in line with
populations without vascular disease.24, 30 Importantly, the findings of our study show
LFCUD did not result in the deterioration of any of the patients in a vulnerable vascular
population.

3.5.1

Limitations

This study had a few key limitations. This trial was an uncontrolled pilot study and
therefore it is not possible to determine whether LFCUD improves healing since there
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was no comparison group. Further investigation through parallel group randomizedcontrolled trial is warranted to determine these outcomes.
Additionally, the sample size was small at ten participants. We determined that ten
patients was a pragmatic number as it allowed us to verify treatment scheduling and
logistical issues for a future trial while also providing sufficient familiarity with the
device for consistent application method in the future trial.
Since we selected patients who did not have exposed bone and tendon, we may have
excluded a large proportion of the vascular surgery wound clinic population, who could
benefit from this treatment. However, we decided to limit our study since osteomyelitis
and associated intractable infection could be more likely with exposed deep structures,
and that these patients may fail to show similar signs of healing progression expected of a
usual vascular population. That said, such patients should be involved in future trials to
better understand this possible effect.
Patients with a variety of lower extremity wound types were included in this study. It is
possible that differences in underlying wound etiology may have affected the consistency
of our results. However, this group of patients is typical of those seen by a vascular
surgery wound clinic, and we considered underlying vascular disease to be the most
important common factor since it was of interest to determine feasibility in clinical
practice.
The duration of the study was limited to 12 weeks so it was not possible to determine an
effect on complete wound closure. However, we believed this to be a reasonable
observation period, since patients with PVD frequently suffer setbacks due to
complicated health issues. With that, we were encouraged to find that none of the wounds
enlarged during the study period.
It is likely that patients under the care of specialized teams would show improvement
even without additional therapies. That said, even with specialist care this population
typically faces frequent deterioration in wound appearance. As such, our finding that no
patient deteriorated is unexpected and encouraging.
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3.6

Conclusion

The results of this study suggest that LFCUD administered by an ET RN in an out-patient
setting to a small group of high risk patients with PVD is feasible to apply weekly, is
safe, and is well tolerated. Wound pain was not a barrier over the course of the LFCUD
treatments. Wound size decreased and wound appearance improved from the baseline
status. Further, the LFCUD treatment did not bring about any treatment-related adverse
reactions.
Additionally, from the results of this trial we are able to calculate a sample size for a
randomized controlled trial to determine a possible treatment effect of LFCUD compared
to a control group (see Appendix 3). We also determined the schedule and design of this
pilot study is suitable for subsequent trials.

3.6.1

Clinical Implications

Our results showed that LFCUD could be applied safely in a supported out-patient setting
by an ET RN. Given that there was no need for additional operating room resources or
medical/surgical personnel, nurse-applied LFCUD could improve access to debridement
procedures. Additionally, making LFCUD more widely available in the supported outpatient clinic may reduce the burden on those critical resources.
A benefit of LFCUD is that it targets necrotic tissue specifically, and, as such, may be
particularly valuable for those considered borderline for debridement. Although caution
is necessary and each patient must be considered in context, failure to remove necrotic
debris and biofilm is not without risk, since this approach may contribute to further
deterioration of the vascular wound. Therefore, an interprofessional team approach
provides the best and safest approach for the use of advanced wound therapies such as
LFCUD.
People with PVD often experience challenges with delayed wound healing, and are at
high risk for limb threatening infections and lower extremity amputations. Additionally,
there may be a limited window of opportunity for healing after a revascularization
procedure since vascular disease represents systemic pathology, and blood flow that is
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restored post-operatively may not be permanently or fully restored. Moving forward, it is
critical that future available and effective methods are implemented to support healing
during the immediate post-operative period. Future research is also warranted to
determine if LFCUD may promote healing in a population with vascular disease and
limited options.
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4

The UltraHeal Randomized Controlled Trial: Effect of 22.5
kHz low frequency contact ultrasound debridement (LFCUD)
on lower extremity wound healing for patients followed by a
vascular surgery service
4.1

Introduction

Patients with wounds complicated by vascular disease are challenging to heal and face
serious health risks. In particular, people who are followed in the vascular surgery wound
clinic include those with arterial disease, venous disease and diabetic neuropathic disease,
which often occur concurrently. Advancing disease results in complicated wounds which
may occur spontaneously as a result of relatively minor injuries or after elective surgical
procedures. These wounds may be considered symptoms of advancing vascular disease
since healing and immune functions are lessened by advancing vascular pathology.
Peripheral vascular disease (PVD) is surprisingly common and has been described as
under-appreciated, under-diagnosed and under-treated.1 Peripheral arterial disease (PAD)
is one form of PVD that involves the vessels that transport blood to the tissues. PAD is
estimated to be present in 29% of the people older than 70 years, and in 29% of people
between 50 and 69 years old who have diabetes or use tobacco.2 Risk factors for PAD
include diabetes, advancing age, cholesterol issues, hypertension, chronic renal
insufficiency, smoking, and family history of cardiovascular disease.3 Patients with PAD
often present with an array of complex medical challenges.
Notably, the presence of diabetes contributes to the development of vascular PVD and
increases the risk of the serious outcomes of infection, amputation and death.
Atherosclerosis is the underlying pathology of PVD and is the factor responsible for most
deaths and morbidity for patients with diabetes.4 Given an increasing elderly population
and what has been described as the economic tsunami of diabetes,5 the number of people
with PAD-related wounds can be expected to increase. In 2010, diabetes affected 7.6% of
the Canadian population, and that figure is estimated to grow to 10.8% by 2020.6
Unfortunately, diabetes also contributes to foot wounds that are the leading cause of non-
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traumatic lower limb amputation.7 To date, there are few conservative treatment
alternatives for people with wounds related to PVD.
Once a wound develops, vascular disease impairs wound healing, and alterations in blood
flow interfere with the delivery and transport of factors essential for cellular function and
healing. Oxygen is particularly important to the performance of cells such as
macrophages and fibroblasts cells that critically influence tissue repair.8 Impaired blood
flow also affects the delivery of systemic medications needed to address illness and
infections.9 A poorly perfused wound environment mutes the inflammatory response,
increasing excess bacterial growth and increasing the risk of infection.10 The repair of
damaged tissue may be so dysfunctional that cell death occurs. This leads to an
accumulation of devitalized tissue (necrosis) in the wound which becomes a food source
for bacteria.19 With poor perfusion, the risk of systemic infection, and even limb
amputation, is increased.
Debridement refers to the removal of any necrotic or unhealthy tissue from the wound
and wound margins,11 and is widely accepted as a fundamental treatment required to
improve the wound environment and promote healing.12-14 Although several forms of
debridement exist, the complete removal of all necrotic tissue leaving a fresh, bleeding
wound base is considered the gold standard for chronic or non-healing wounds as it can
restart acute cellular repair processes. Debridement to bleeding tissue also removes old
and inactive cells to refresh advancing wound edges.15, 16
Sharp debridement is thought to reduce wound bacteria, including those present in
biofilms.17 This is important because biofilm bacteria are present in at least 60% of
chronic wounds.18 Bacteria that develop in protective biofilm colonies are problematic
since they are notoriously hard to remove or destroy, are very difficult to detect and are
believed to be the root cause of recurring wound infections.19
Although debridement to bleeding may have several benefits, these procedures are
demanding of clinician time, skills and resources. As such, debridement that induces
bleeding is not readily available in many clinical settings.20 In many areas inadequate
funding models may be in place to reimburse physicians for the time required for
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debridement. Non-physician clinical staff may have insufficient education or experience,
varying levels of competencies, and lack of clear policies which form barriers to
performing debridement.21 Alternative options, such as low frequency contact ultrasound
debridement (LFCUD) are of interest as they could improve access to care for the
vascular population.

4.1.1

Benefits of Ultrasound

Ultrasound is acoustic energy in the form of sound waves above the range of human
hearing (greater than 20,000 kHz).22 There are several variations of therapeutic
ultrasound used to treat wounds including indirect and direct contact methods that may be
directed either to the wound or peri-wound area. These applications incorporate a range
of frequencies, and formats of ultrasound delivery that may be delivered in continuous or
pulsed (intermittent) modes. Higher frequency (MHz) applications are applied using a
transducer to the peri-ulcer skin and coupled via aqueous gel, or through a water bath
medium. Lower frequency therapeutic systems (kHz) are available that deliver ultrasound
by probes or through saline vapor. The lower frequencies produce a longer wavelength
which penetrates tissue more deeply and generates less heat compared to higher (MHz)
frequencies.22 Although these various modes are all based on ultrasound energy, it is
inappropriate to compare them directly since indications, dosage and delivery methods
are not equivalent. The focus of this study is to explore the effect of LFCUD, which is a
direct wound contact application of ultrasound that immediately and visibly removes
necrotic debris and causes a light bleeding response.

4.1.2

Physiological Effects on Healing

Ultrasound has been shown to promote cellular response, including, fibroblast activity,
collagen deposition and new blood vessel growth to induce tissue repair.23-26 Ultrasound
has also been shown to induce blood vessel dilation27 and improve the quality of
granulation tissue.25, 28 More recently, there is emerging evidence that ultrasound
promotes migration mechanisms and promotes cell adhesion, which is necessary for
tissue repair to occur.29 Interestingly, increase of local blood flow, oxygen uptake and
tissue regeneration in embryo tissues have all been noted with ultrasound application.30
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These particular attributes are of interest for a vascular population. In light of these
benefits, our study examines the combination of ultrasound and debridement.

4.1.3

Bactericidal Effects

It is also possible that ultrasound may help treat infection since it aids to dismantle,
remove and damage bacteria, including those in the aforementioned biofilms. As early as
1980, Schoenbach and Song found that five minutes of low frequency ultrasound (20
kHz) applied indirectly by water bath decreased Pseudomonas Aeruginosa bacteria in rats
with septic burn wounds.31 The ultrasound permitted survival and wounds progressed to
epithelization and healing. In comparison, 25% of the control group died from
complications associated with sepsis, and wounds in this group appeared ulcerated and
covered with necrotic eschar.
The effectiveness of antibiotic therapy appears to be enhanced with ultrasound. One
study found that pseudomonas biofilm was more susceptible to the antibiotic gentamicin
when ultrasound frequencies of between 70 kHz and 10 MHz were applied. The lowest
frequency ultrasound (70 kHz) produced the most pronounced synergistic effect of
ultrasound and antibiotics.32 Another study found the same low frequency ultrasound
dismantled the protective blocking effect of Pseudomonas Aeruginosa, and more than
doubled the transport of gentamicin through Escherichia Coli biofilms.33 This synergistic
effect has been described between ultrasound and several classes of antibiotics, producing
a declining bacterial effect of several orders of magnitude.34 Interestingly, a similar antifungal effect was noted in an in vitro study.35 Ultrasound is thought to work in part by
making biofilm bacteria vulnerable to antibiotic penetration and speeding up bacterial
metabolism. This results in a greater uptake and processing of antibiotics by the bacteria,
which, in turn, promotes bacterial death.36
LFCUD devices incorporate potentially beneficial ultrasound energy to precisely remove
debris while causing minimal disturbance of viable tissue.37 There is emerging evidence
that LFCUD may support healing in several challenging wound applications. For
example, LFCUD has been used to support skin graft patients with various wound
types,38 and to permit successful closure after prosthetic vascular graft infection.39
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LFCUD is also thought to shorten the time to secondary closure of infected sternocutaneous fistulae in cardiac surgery patients.40 A similar form of LFCUD has been used
to remove plaque biofilm in dentistry while also reducing damage to gum tissue from
instrumentation.41 While early wound studies using LFCUD are promising, the healing
response of a population with vascular disease has yet to be explored.

4.1.4

Study Rationale

The vascular population is very susceptible to delayed wound healing and wound
infection which can be difficult to eradicate and can delay wound closure. Ineffective
wound healing and advancing infection may result in serious consequences that include
limb amputations, extended hospital stays and even death.
Debridement is the gold standard to remove necrotic tissue and restart an acute healing
response. Ultrasound and debridement may have a synergistic effect to support tissue
repair. Ultrasound includes bactericidal effects that potentially disrupt biofilms and boost
the effectiveness of antibiotics. However, since LFCUD is a newer technology, it has not
yet been studied in a controlled clinical trial to investigate patients with PVD.

4.2

Research Purpose

The purpose of this study is to explore the effect of adding 22.5 kHz LFCUD to usual
care on wound healing outcomes of a vascular surgery wound clinic patient population. It
is hypothesized that treatment with LFCUD will remove necrotic debris, reduce bacterial
burden and stimulate the rate of wound healing in the vascular population. It is also
hypothesized that improved healing times will also reduce complication events of
infection, amputation and health care system usage in this high-risk population. Using
this prospective randomized controlled study design, the following study questions will
be addressed:
1. Does four weeks of treatment with LFCUD added to usual wound care improve
wound healing outcomes compared to a similar group of patients receiving usual
care?
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2. Does the application of ultrasonic assisted debridement reduce bacterial load
and lower clinical signs of infection in a vascular population compared to usual
care?
3. Does the application of LFCUD in a high risk population of patients with PVD
improve patient outcomes and complications, including, amputations, deaths,
emergency room visits and admission days?

4.3

Methods

The study is comprised of a two arm prospective randomized controlled trial with single
assessor blinding. The sample size calculation is presented in Appendix 3. A study flow
diagram is outlined in Figure 5. The study was approved by both Western University and
Ottawa Hospital Research Institute Research Ethics Boards as required (see Appendices 1
and 2). The study was registered at the U.S National Institutes of Health Registry
(ClinicalTrials.gov, at identifier NCT01973361). As per local requirements for the
administration of LFCUD by an ET RN, the Department of Vascular Surgery approved a
Medical Directive and a Delegated Medical Act. The ET RN, who is a specialized nurse
with graduate education in wound care, completed the screening process and provided
patients with a letter of information that was approved by the Research Ethics Boards.
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Figure 5 Patient flow diagram

Screened
(n = 103)

Excluded (n = 33)
Logistical reasons (n = 12)
Medically unstable (n = 4)
Exposed bone/tendon (n = 6)
Non-English speaking (n = 1)
Wound <1cm2 (n = 7)
Pacemaker Device (n = 2)
Renal transplant (n = 1)

Allocation

Randomized (n = 70)

LFCUD + Usual Care
(n = 33)

Usual Care
(n = 37)
Withdrawn
prior to
treatment,
exposed bone
therefore no
longer eligible
(n = 1)

Treatment

Withdrawn prior
to treatment,
concerned
LFCUD might
cause pain
(n = 1)

(n = 32)

(n = 36)

Withdrawn
once treatment
commenced
(n = 3)

Analysis

Withdrawn
once treatment
commenced
(n = 2)
Post-Treatment
Week 5
Analyzed (n = 32)

Post-Treatment Week
5
Analyzed (n = 36)

Follow-up Week 12
Analyzed (n = 32)

Follow-up Week 12
Analyzed (n = 36)
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All patients with lower extremity wounds of at least 1cm2 in size, who were referred to
the vascular service of a tertiary care hospital, were approached consecutively by
members of the vascular service team and asked if they would participate in the study.
Patients were eligible if they were over 18 years of age, and had a full thickness wound
below the knee greater than 1cm2 in surface area. Patients were excluded if they had
conditions that prevent healing or if they had a medical condition that could
contraindicate ultrasound treatment or could cause undue pain or post procedural
bleeding. Patients were also excluded if they were concurrently receiving alternate
advanced therapy treatments, had exposed bone or tendon in the wound, or were
unwilling to complete the 12 week study protocol. Patients with more than one ulcer
were included and all ulcers were treated. However, only one ulcer (the largest area
measured at baseline) was followed for study purposes. All patients were screened by a
vascular surgeon and the Infectious Diseases (ID) physician to rule out the presence of
serious or potentially life or limb threatening ischemia or infections.

4.3.1 Vascular Assessment
All patients underwent an extensive vascular assessment by one of six vascular surgeons.
Typically, this included palpation of pedal pulses. If pulses were not appreciated or if
there were any other vascular concerns, there was an evaluation of limb perfusion using
various methods performed as part of usual care. Vascular tests used in this study
included the evaluation of Ankle Brachial Pressure Index (ABPI) or Toe Brachial Index
in a clinical vascular laboratory as well as more invasive tests such as computerized
tomography angioplasty or digital subtraction angioplasty. As part of the screening
process, the vascular surgeon confirmed that vascular status was sufficient for healing
and that debridement was not contraindicated. Throughout the study, the vascular
surgeons were not blinded so that patients could discuss any concerns and safety could be
monitored.

4.3.2

Randomization

All eligible and consenting patients were enrolled and randomly allocated during their
baseline visit. Patients were allocated to the low frequency contact ultrasound
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debridement (LFCUD) group plus usual care or just usual care (UC) by a concealed
computer-generated sequencing method. The computer program stratified patients who
were receiving negative pressure wound therapy (NPWT) for equal distribution between
groups. Typical of this population, 25 patients (36.8%) were receiving negative pressure
wound therapy. The stratification process resulted in 11 (34.4%) patients receiving
NPWT in the LFCUD group and 14 (38.9%) in the UC group. This concealed
stratification and allocation process was performed by a university-based computer
system (Empower, Inc., London, Canada), which was off-site and independent of any of
the researchers.

4.3.3

Infectious Diseases Assessment

All patients were assessed for infection by the same ID physician who was blinded to
treatment allocation. This physician had previous extensive training and experience in
debridement procedure, tissue biopsy and infection analyses which included clinical
impression. Additional training was provided regarding entering the data into the
computerized database and using the infrared thermometer for taking wound temperature.
As part of this assessment, the ID physician obtained a tissue sample for analysis. Briefly,
these samples were obtained by 3mm dermal punch biopsy or scalpel after cleansing with
physiological sterile saline. An extensive debridement procedure was then performed to
remove all necrotic tissue in the wound surface. This sharp debridement procedure
involved cleansing with chlorhexidine 0.05% and completely removing all visible
necrotic debris on the wound surface with sterile curette, forcep and/or scalpel. The ID
physician determined at this visit whether the wound was infected or not, and antibiotics
were prescribed as needed according to the Infectious Diseases Society of America’s
Practice Guidelines for Skin and Soft Tissue Infection42 and Diabetic Foot Infection.43
An accredited medical laboratory then analyzed the samples semi-quantitatively in
aerobic and anaerobic conditions.

4.3.4

Initial Assessment

The study timeline is outlined in Figure 6. All patients who were enrolled in the study
underwent a comprehensive assessment conducted by the ET RN to identify risk factors
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for delayed healing. A patient history form was used to fully describe patient
characteristics and identify all co-morbidities known to affect healing (e.g. diabetes and
associated complications, any recent or serious illness and/or any recent surgeries). A
blood sample was drawn to identify factors that may affect healing (e.g., infection,
nutritional markers, and anemia). The ET RN applied the treatments and therefore was
not blinded to treatment allocation.

4.3.5 Wound Assessments
Wounds were assessed at each visit by the Registered Practical Nurse assessor (RPN),
who is a nurse familiar with wound care. This RPN was trained to photograph and trace
the wound, compute planimetry measurements, determine visual analogue scores (VAS)
for pain, and enter data into the computer database. This nurse assessor was blinded to
treatment allocation and performed assessments prior to any treatments so that visual
cues of group allocation were absent.
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Figure 6 Study visit diagram

Treatment Phase

Recruitment

Consecutive Referral from Vascular Surgeon

Screening
Vascular Assessment
Baseline Assessment Week 0
Vascular surgeon evaluation
Demographic information and blood test
ID physician evaluation: Sharp wound debridement and assessment of wound
infection†
Wound healing (wound size, pain score, and revPWAT score)††,
Randomization (Stratified for NPWT)
1st Treatment (Week 1)
LFCUD + UC
Wound healing (wound size, preand post-treatment pain score)††

1st Treatment (Week 1)
UC
Wound healing (wound size,
pre- and post-treatment pain
score)††

2nd Treatment (Week 2)
LFCUD + UC
Wound healing (wound size, preand post-treatment pain score)††

2nd Treatment (Week 2)
UC
Wound healing (wound size,
pre- and post-treatment pain
score)††

bridement + usual care
3rd Treatment (Week 3)
LFCUD + UC
Wound healing (wound size, preand post-treatment pain score)††

Ultrasound debridement +
usual care
4th Treatment
(Week 4)

Follow-up

LFCUD + UC
Wound healing (wound size, preand post-treatment pain score)††

3rd Treatment (Week 3)
UC
Wound healing (wound size,
pre- and post-treatment pain
score)††
4th Treatment (Week 4)
UC
Wound healing (wound size,
pre- and post-treatment pain
score)††

Post-treatment Week 5 (1 week after last treatment)
Wound healing (wound size, pain score, and revPWAT score)††
ID physician evaluation: Sharp wound debridement and assessment of
wound infection†
Post-treatment Week 12
Wound measurement, pain score and wound
photography††

Complications

†Wound infection assessed via semi-quantitative analysis of tissue sample culture and visual wound inspection
††Wound measurement, photography and pre-treatment pain scores obtained and documented by blinded
nurse assessor. Abbreviations: LFCUD = Low Frequency Contact Ultrasound Debridement; UC = Usual Care;
revPWAT = Revised Photographic Wound Assessment Tool 45
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4.3.6

Usual Care (UC)

All patients in the control group, known as usual care (UC), continued to receive routine
wound care on the same visit frequency as the treatment group. In the vascular wound
clinic, usual wound care includes removing/observing the dressing, cleansing the wound
with chlorhexidine 0.05%, performing a conservative sharp debridement of any necrotic
debris from the wound base, pairing the periwound callus, and replacing with a dressing.
For the study, patients in both groups received a consistent silver alginate dressing
(Silvercel®, Acelity, San Antonio, TX)

4.3.7

Negative Pressure Wound Therapy (NPWT)

For patients with cavity wounds that extend adjacent to deep structures or with postoperative cavity defects, usual care includes the use of NPWT as the wound dressing. For
these patients, one of two NPWT devices was used (VAC®, Acelity, Antonio, TX, or
Renasys®, Smith & Nephew, London, UK). NPWT was set at intermittent suction to
support granulation response unless wound structural support was needed or the seal was
problematic in which case continuous suction was selected. To reduce the influence of
this active therapy on study outcomes, patients were evenly distributed between groups
by computer stratification during the process of random allocation.

4.3.8

Low Frequency Contact Ultrasound Debridement (LFCUD)

In addition to routine wound care, all patients assigned to the treatment group received
high intensity, low frequency (22.5 kHz) contact continuous ultrasonic debridement
(Sonic One®, kindly supplied by, Misonix, Farmingdale, NY. [See Appendix 4]). The
hand-piece and probe were sterilized in the central processing department by autoclave as
per manufacturer’s instructions. Treatment continued until light bleeding occurred and all
necrotic tissue was removed. The treatment was applied by placing a sterile probe in
direct contact with the wound bed. The Sonic One® LFCUD device produces a 22.5 kHz
ultrasonic frequency at amplitude settings of one to five through a piezoelectric crystal in
the hand piece which, in turn, transfers the acoustic energy into the tissue via direct
contact with the saline medium. The saline irrigation rate was set at the lowest setting.
The probe type was selected based on patient pain sensation, wound shape and tissue
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adherence. The gold (standard) probe was the usual selection while the green (gentle)
probe was used for patients with any described discomfort or preference, the blue (tunnel)
probe was used for wounds with undermined areas, and the magenta (aggressive) probe
was used for very adherent necrotic debris.

4.3.9

Treatments

All treatments were administered under medically aseptic conditions in the combined
vascular surgery in-patient and wound clinic setting. The probe type was recorded at all
sessions, and all hand-held probe attachment components were autoclaved at the hospital
instrument processing centre prior to every treatment and returned in sterile packaging for
the next use. Personal protective equipment, including a face visor, was used for the
aerosol generating procedure22 as per local infection control practices. Local anesthesia
was available by injection prior to the LFCUD procedure. Each patient was informed at
the initial visit and in the study letter of information that local anaesthesia was available
on request if they felt uncomfortable. Additionally, patients were reminded that local
anaesthesia was available if they appeared uncomfortable at any point during their visit.
Treatment was applied until necrotic debris was removed and light bleeding achieved at
each of the four weekly treatments by the ET RN who had received training and
certification on use of the device from the company representatives (Misonix,
Farmingdale, NY).

4.3.9.1

Wound Size

Wound surface area was recorded by the RPN who traced the wound perimeter three
times onto a multi-layer acetate designed for single patient use (Visitrak, Smith &
Nephew, London, UK). All tracings at the treatment visits were taken after cleansing the
wound and before debridement at treatment visits (Week 1 to Week 4)so that visual cues
to treatment allocation were not present. Tracings were obtained after the ID physician
debridements at Week 0 and Week 5 so that necrotic debris did not obscure the wound
edges. Tracings were digitized using the previously validated Visitrak planimetry
system44 (Smith & Nephew, London, UK), and the mean of three tracings was calculated
to determine the area in centimetres squared (cm2) with minimal error of measurement.
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4.3.9.2

Wound Closure

Wound closure was determined by the RPN by a wound measurement of 0cm2 and
absence of exudate, which was subsequently confirmed by the ET RN.

4.3.9.3

Wound Appearance

Using a Canon Rebel 300D EOS, 8 megapixel resolution, 60mm macro lens digital
camera with a ring flash, automatic focus photographic images were taken to assess
wound appearance. In order to assess the wounds using the rev Photographic Wound
Assessment Tool (revPWAT), the patient was positioned in a similar fashion in a room
that has the same examination lighting. The wound dressing was removed and then a
ruler was placed against the skin near the wound and labelled with the subject ID number
and the date the photo was taken. Digital images were captured after wound cleansing
but before any debridement (to prevent visual cues of group allocation) at the beginning
of treatment sessions (Weeks 1-4). The digital image was assigned a de-identified
number that was not linked to the patient or the session. In this way, the single assessor
who evaluated all photographs, which were mixed and assessed in large groups, did not
know who had received LFCUD or the sequence of visit when the photo was taken.
Each photo was assessed using by using a validated scoring tool called the revPWAT,.45
which is a pen and paper tool that is used to systematically assess eight different
characteristics of the wound base, edges and peri-ulcer skin using a photograph of the
wound and peri-ulcer skin. Each of the eight domains of the revPWAT is ranked on a
four point scale with zero representing a closed wound and 32 signaling the highest
possible score.

4.3.9.4

Pain

Pain was measured using the validated Visual Analogue Scale (VAS).46 This involved
asking the patient to identify on a 100mm ruler with slide indicator, the level of wound
pain experienced with 0mm = no pain, and 100mm representing the worst pain
imaginable. This question was asked by the blinded RPN assessor at the beginning of
every visit. The VAS pain score was re-evaluated immediately after treatment by the ET
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RN who did all the debridement procedures. Each assessor recorded their results
independently into the computer database.

4.3.9.5

Complications

The number and type of hospital admissions, amputations and deaths were recorded and
reported to the relevant ethics boards.

4.3.10 Statistical Analysis
Data were analyzed using SPSS version 23.0 (SPSS, IBM Corporation, Armonk, NY).
Baseline characteristics were compared between groups by X2 Test for categorical data
and Student’s t-Test for continuous variables. The wound healing outcome data of change
in wound surface area (cm2) and total revPWAT scores were calculated using a covariate
analysis (ANCOVA) to adjust for baseline. A two-sided p- value of <0.05 was considered
statistically significant and all patients were analyzed in the group to which they were
allocated. All missing data, which included patients who withdrew once treatment started,
were imputed with the last outcome carried forward.

4.4 Results
One hundred-and-three patients were recruited for the study from December 2013 until
May 2015; however 33 were screened out during the initial assessment. Of the 33
patients who were screened out, 12 declined to participate for multiple reasons (e.g.,
parking costs and frequency of visits); seven had wounds that were smaller than 1cm2 in
area; six had an exposed bone or tendon visible in the wound; four were medically
unstable; two had pacemaker devices in situ; one did not speak English; and one had a
previous renal transplant (see Figure 5).
A total of 70 patients were randomly assigned to either the experimental group (LFCUD)
or the control group (UC). Of the 70 patients, two patients withdrew at the initial visit
(after the randomization had occurred), one patient chose not to continue in the study
(due to concerns about the potential treatment pain), and the other patient originally
assigned to the UC group had exposed bone after initial sharp debridement and therefore
was no longer eligible. In total, 68 patients received one of the two treatment
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interventions with 32 patients allocated to the LFCUD group and 36 patients to the UC
group.
Of the 68 patients followed in the study, five patients (three in UC group and two in
LFCUD group) withdrew later in the treatment phase. However, they had attended most
treatment visits and were equally distributed between groups. These patients withdrew
for: practical reasons such as parking costs and frequency of visits (n = 2, UC group);
medical issues including medical decline to palliative status (n = 1, LFCUD group);
infection requiring toe amputation (n = 1, UC group); and change of treatment plan
initiated by homecare nurse (n = 1, LFCUD group). None withdrew as result of the
treatments. In addition to those who withdrew, there were ten patients who missed one
treatment visit (including eight patients receiving UC treatment and two patients
receiving LFCUD) due to practicality of visit reasons. Including both withdrawals and
missed visits, a total of 16 patients (23.5%) did not return for evaluation at the 12 week
follow-up visit. All data were included and missing information was imputed with the last
outcome carried forward to provide an intention-to-treat analysis for conservative
estimation of treatment effect.

Patient Characteristics
For information on all patients in the study, see Table 8. Of the patients in the study, most
were male and the majority had evidence of significant vascular disease (having
undergone either a previous angioplasty or bypass procedure or a major or distal
amputation). Patients in the LFCUD group had a longer mean duration of diabetes, longer
wound duration, lower hemoglobin and fewer bypass graft procedures, but these
differences were not statistically significant. Of the 47 patients with diabetes, the disease
was advanced with mean duration of 20.5 years. Twenty-three patients in the LFCUD
group had diabetes (48.9%), as did 24 patients in the UC group (51.1%). There were
more patients in the LFCUD group who had undergone previous trans-metatarsal or
digital amputation procedures, and this was statistically significant (X2(1) = 5.88, p =
0.015). Mean ankle brachial pressure index (ABPI) was significantly lower in the
LFCUD group (0.83, p = 0.033), but this was calculated from an incomplete sample (n
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25) since many patients had other forms of vascular testing. Additionally, a greater
proportion of the patients in the UC group had a wound infection when they were
enrolled (33%) than those in the LFCUD group (19%), but this difference was not
significant between groups (X2(1) = 1.85, p = 0.174).
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Table 8 Demographics of Patients in LFCUD and UC Groups

Age (Years)
Male
BMI
Initial Wound Area (cm2)
Wound Duration
(Months) (n= 76)
Wound infection at
baseline visit
Wound Location
Toe/ Toe
Amputation Site
Mid-Foot/Plantar
Heel
Malleolar
Leg
Diabetes
Duration Diabetes
(Years) (n= 45)
Anti-coagulant
Medication
Antibiotic Medication
Hemoglobin (n = 77)
HbA1C
Albumin (n = 70)
NPWT
ABPI (n = 25)
Arterial Insufficiency
Pedal Pulse Present †
Angioplasty
Bypass Graft
Prior Amputation:
Major: (Transtibial/
Transfemoral)
Distal: (Pedal/Digital)

Total Sample

LFCUD

UC

(n = 68)

(n =32)

(n = 36)

p - value

65.71 ±10.49
76.5 (52)
26.43 ± 5.61
14.64 ± 20.25

67.22 ± 11.49 64.36 ±9.50
75.0 (24)
77.8 (28)
25.1 ± 4.84
27.61 ± 6.05
13.55 ± 23.35 15.64 ± 17.31

p = 0.265
p = 0.788
p = 0.065
p = 0.675

14.75 ± 27.32

17.06 ±36.85

12.57 ± 13.57

p = 0.675

25.5 (18)

18.8 (6)

33.3 (12)

p = 0.174

16.2(11)

15.6 (5)

16.7 (6)

p = 0.907

27.9 (19)
20.6 (14)
7.4 (5)
27.9 (19)
69.1(47)

31.3 (10)
18.8 (6)
9.4 (3)
25.0 (8)
71.9(23)

25.0 (9)
22.2 (8)
5.6 (2)
30.6 (11)
66.7 (24)

p = 0.566
p = 0.724
p = 0.660
p = 0.610
p = 0.643

20.56 ±12.30

22.23 ± 13.72

18.96 ±10.85

p = 0.379

64.7 (44)

65.6 (21)

63.9 (23)

p = 0.881

64.7 (44)
114.21 ± 18.99
7.61 ±1.45
31.4 ±5.68
36.8 (25)
0.92 ± 2.34
n = 60
18.3 (11)
55.0(33)
33.3 (20)

62.5 (20)
112.2 ± 17.33
7.59 ± 1.24
30.9 ± 6.67
34.4 (11)
0.83 ± 0.19
n = 29
13.8 (4)
55.2 (16)
27.6 (8)

66.7 (24)
116.1 ±20.47
7.63 ± 1.65
31.84 ± 4.65
38.9 (14)
1.03 ± 0.25
n = 31
22.6 (7)
54.8 (17)
38.7 (12)

p = 0.720
p = 0.409
p = 0.933
p = 0.541
p = 0.700
p = 0.033*

11.7 (7)

6.9 (2)

16.1 (5)

p = 0.426

30.0 (18)

44.8 (13)

16.1 (5)

p = 0.015**

p = 0.416
p = 0.979
p = 0.361

Unless otherwise stated values expressed as mean ± Standard Deviation with range in parentheses, or
percentage (n). Abbreviations: LFCUD = Low Frequency (22.5 kHz) Contact Ultrasound Debridement; UC
= Usual Care; BMI = Body Mass Index; HbA1C = Glycated Hemoglobin; NPWT = Receiving Negative
Pressure Wound Therapy to wound.
†
Pedal Pulse Palpable = Dorsalis Pedis and/or Posterior Tibial pedal pulse palpable in affected limb.
*
Statistically significant difference but partial sample only: t(23)= -2.270, p = 0.033, n = 25.
**
Statistically significant difference: X2(1) = 5.88, p = 0.015
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4.4.1

Ultrasound Debridement Treatments

LFCUD was consistently applied in continuous mode at amplitude five with
physiological saline flow at 20% until surface debris was removed and light bleeding
response was obtained. The average length of LFCUD treatment was two minutes and 59
seconds (with a range from 19 seconds to six minutes). Most patients were treated with
the green (gentle) probe (44.0 % and the gold (regular) probe (40.8%). Two patients
received a total of six treatment episodes with the blue (tunnel shape) probe due to wound
shape (4.8%), and one patient received the magenta (aggressive) probe at two visits
(1.6%) to treat adherent slough.

4.4.2

Wound Appearance (revPWAT score)

The LFCUD group demonstrated a significantly greater improvement in wound
appearance (M = 7.34, 5.81 – 8.88, 95% CI) than the UC group (M = 2.98, 1.36 – 4.60,
95% CI). Put another way, there was improved wound tissue appearance in the LFCUD
group by 4.36 points (2.07 – 6.66, 95% CI). This significant difference between groups
was found after controlling for baseline revPWAT score as a covariate (p = <0.01, Figure
7).
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Figure 7 Change in wound appearance (week 0 – week 5)

*
Baseline -Week 0

Post Treatment – Week 5

Abbreviations: LFCUD = Low Frequency Contact Ultrasound Debridement; UC = Usual Care; revPWAT = revised
Photographic Wound Assessment Tool. * Change in wound appearance was significantly greater in the LFCUD group
post-treatment (week 5) after controlling for baseline revPWAT score (p = <0.01)

4.4.3

Wound Surface Area (WSA)

There was progressive trend in decreasing wound surface area (WSA) over the four
weekly LFCUD treatments (see Figure 8), which was significant (p = <0.01) but this
trend was not found to be significant for patients in the UC group (p = 0.935). However,
the mean difference in percentage WSA reduction between groups was not statistically
significant (p = 0.485) as calculated using the WSA baseline as a covariate in the analysis
of covariance (ANCOVA) test. This mean %WSA reduction post-treatments (Week 5)
was greater (31.63%, 3.54 – 59.70, 95% CI) in the LFCUD group than in the UC group
(18.06%, -8.42 – 44.54, 95% CI), but not significant. Two patients in the LFCUD group
had closed wounds by Week 5, and two others had been transferred to plastic surgery for
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skin grafting. None of the UC group had closed wounds at Week 5 or were ready for skin
grafting.
Figure 8 Percentage change in wound size from baseline

Abbreviation: LFCUD = Low Frequency Contact Ultrasound Debridement, UC = Usual Care.
(Baseline wound surface area (WSA) = 100%). Linear trend in WSA reduction was significant (p = <0.01) for LFCUD group
during treatment period (from week 0 – 5) but not significant for UC p = (0.935) as adjusted not assuming equal variances

4.4.4

Infection

Both the experimental LFCUD group and the UC group had a reduced number of wound
infections after the treatment phase. From the baseline to the post-treatment visit, the
wound infection rate in the LFCUD group decreased from 18.8% to 12.5%. Similarly, the
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wound infection rate in the UC group reduced from 33.3% to 11.1%. That said, this
change was not significant between groups (p = 0.317, Wilcoxian Signed Ranks Test).
During the four weekly treatment visits for LFCUD or UC, six patients developed a new
infection.
Patients reported a decrease in pain after LFCUD at every visit, which was statistically
significant. The difference in mean pain scores during the four treatment visits ranged
between 9.3mm (3.5 – 15.1, p = 0.003, 95% CI) at Week 3, and 16.6mm (9.0 – 24.2, p =
<0.001, 95% CI) at Week 2. However the UC group had a significant difference only at
Week 1 of 6.11mm (0.152 – 12.1, p = 0.045, 95% CI). Patients receiving LFCUD
commonly reported a sensation of vibration rather than pain and frequently noted that
they were surprised since they had anticipated pain at the first application. Two patients
requested a local anaesthetic at initial treatments, which was administered by the ID
physician or vascular physician prior to treatment. Both of these patients did not require a
local anaesthetic for other treatments since wounds improved and they became more
comfortable.

4.4.5

Adverse Events

Adverse events were rare, and none were related to a treatment. In total there were 12
adverse events, including six in the LFCUD group and six in the UC group. In the
LFCUD group, there were: two new infections; one arterial occlusion requiring
admission to hospital for angioplasty; one dressing reaction; one burn injury from a house
fire; and one death which occurred several weeks after treatment had concluded. In the
UC group, four patients developed new wound infections; one patient developed an
infection requiring toe amputation; and one patient developed a medication-related rash.
In total, six patients (two in the LFCUD group and four in the UC group) were diagnosed
with new infections during the study. This included one emergency room admission and
toe amputation related to a new wound infection in a UC group patient. As per the REB
requirements, all complications were reported to the Data Safety Monitoring Board, and
were later deemed unrelated to the device by both the blinded ID physician and the
unblinded vascular surgeons.
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Patient experience during ultrasound debridement was generally favourable.
Interestingly, there was minimal bleeding with ultrasound debridement despite most
patients receiving anticoagulant therapy. Many patients in the LFCUD group reported
they believed the treatment was improving their wound, and one patient reported restored
sensation to his forefoot that had been absent for an extended time. It is possible that
local angiogenesis was increased as a result of the ultrasound, providing improved
perfusion and nerve function. No patients perceived wound deterioration from the
treatment.

4.4.5.1

Follow Up: 12 Week WSA

Of the 47 patients who attended the 12 week follow up visit, the mean WSA was smaller
in the LFCUD group at 4.83cm2 (-10.673 – 1.85, 95% CI) than in the UC group, where
the mean WSA was 9.25cm2 (-10.56 – 1.74, 95% CI). However, this difference in WSA
was not statistically significant (t(46) = -1.42, p= 0.163). Put another way, 18.4% of the
LFCUD group attained a wound size of less than 6cm2 compared to 36% of the UC
group. Of the patients assessed at 12 weeks, seven (24.1%) in the LFCUD group had
closed wounds compared to three (9.1%) in the UC group.
The results of this study demonstrate that four weekly LFCUD treatments resulted in a
significantly improved wound appearance as well as a WSA reduction trend in a vascular
population with challenging wounds. Importantly, LFCUD was well tolerated, did not
induce additional pain, and did not bring about any treatment-related adverse events.
LFCUD was feasible to apply by the nurse in a vascular wound clinic. LFCUD
successfully facilitated the removal of necrotic debris without the need for a surgical
team or operating room.
Although the LFCUD group had a greater change in mean WSA than the UC group, this
finding was not statistically significant. However, we did find a significant trend in WSA
reduction that was not noted in the UC group. In our pilot study we were pleased with
achieving a 39.4% mean WSA reduction after four weekly treatments since a vascular
population may have healing challenges. In the current study, although we achieved a
similar 31.6% reduction mean WSA with LFCUD, some variability of wound
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progression in the UC group may have reduced the ability to detect a significant mean
difference in WSA. The finding that the mean WSA for UC (18.06%) was similar to our
anticipated rate of healing for non-healers, and was similar to the sample size calculation
estimated at 19.4% supports this view. However, since our findings did not achieve
statistical significance, we cannot draw conclusions on the difference in WSA from this
trial.
A previous study showed that weekly LFCUD treatments (25kHz) applied to diabetic
foot ulcers with osteomyelitis accelerated wound healing when compared to UC group at
two and three month time-points.47 When compared to our study, it is possible that a
single wound type with an extended period of time yielded these effects since those
patients received over twice as many treatments. As such, it could be that the four
treatments administered in our study were insufficient in number to show a significant
effect. Additional treatment time could improve wound contraction. That said, treatment
was given until light bleeding was achieved, and extended treatment times could deepen
the wound.
Based on prior studies, we believed our schedule would be feasible and reasonable to
attain a treatment effect. For example, one study51 found seven out of 19 patients healed
chronic leg ulcers with a LFCUD treatment every two to three weeks and a total average
of five or six treatments. Another study used the same schedule, permitting some wounds
to be ready for skin grafting.38 The ideal timing between LFCUD treatments has yet to
be determined. Even though it is known that an increase of conventional sharp
debridement sessions promotes hastened wound contraction,13 there is no consensus on
the best schedule with that method to achieve the greatest effect. It is unlikely that it
would be feasible in our population with advancing vascular disease to increase the
number of treatments per week or the number of weeks the treatment is applied. Given
that treatment schedules were varied in previous LFCUD trials, we designed our visits to
fit usual and reasonable clinic scheduling and to reflect the range of similar studies.
Our findings show that applying LFCUD results in a significant improvement of wound
appearance (Figure 7). Furthermore, our wound assessment occurred one week after
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treatment and therefore the improved wound appearance effect was lasting. This change
of wound appearance was largely due to less necrotic tissue and improved granulation
tissue appearance. Since this is the first study to evaluate the effect of LFCUD on wound
appearance using the revPWAT validated wound assessment tool, we cannot determine if
this effect is consistent with other populations. However, Herberger and colleagues
reported a subjective improvement in wound appearance, positing LFCUD treatment is as
equally efficient as surgical wound debridement.52 For a complicated vascular population,
it is possible that wound depth and severity influences the speed of wound contraction. It
is also recognized that, as unhealthy tissue is removed, some increase in wound size is
expected and viewed as positive progress.48 Additionally, since wound depth can be
difficult to measure consistently, evaluating the wound appearance may be the best early
measure of progress for more extensive wounds. The improvement of wound appearance
among LFCUD patients was not surprising as this finding reflects the results of previous
in vitro and animal studies.28, 49
This is the first time that LFCUD has been shown to produce a significant improvement
in wound healing outcomes for patients with PVD. Our results of early wound
improvement are consistent with a previous study which examined diabetic foot ulcers
with osteomyelitis.47 However, results in that study are difficult to interpret over extended
time because of possible variations in antibiotic treatments common to that population.
Our data do not confirm that LFCUD has an effect to diminish the recurrence of infection
or biofilms. However it is widely accepted that biofilms form more readily on inert or
dead material,54 and since wound appearance was improved the environment was
rendered less conducive for bacterial growth after treatments. It is also possible that the
LFCUD administration time was too short or too infrequent to note a significant effect.
Additionally, as we have previously explored in Chapter 2 of this document, signs of
bacterial burden and infection are difficult to detect in this population. Furthermore,
patients were receiving a variety of antibiotic therapies and were at various stages within
that therapy. Given these circumstances, it could be that it was not possible to isolate the
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effect of LFCUD within the “noise” of medical therapies. Further research is warranted
as emerging and more precise methods of wound infection diagnosis become available.
Surprisingly, we found pain was significantly reduced in the LFCUD group after each
debridement experience. In our experience, sharp debridement procedures are frequently
painful which is unpleasant for the patient, and often require local anaesthetic. However,
patients receiving LFCUD commonly reported a sensation of vibration rather than pain
and frequently noted that they were surprised since they had anticipated pain at the first
application. This is encouraging since anxiety and stress affect healing.50 Our findings
again reflect those of previous researchers, who have found patients with chronic leg
ulcers treated with LFCUD reported little pain,51 and that LFCUD was less painful than
surgical debridement.52 We were pleased to note that LFCUD induced little discomfort,
and did not worsen the baseline pain status. This finding confirms our previous results
from the pilot study, and suggests that the LFCUD approach may be less painful than
current usual practice.
The patient group in our study was different than previous populations as we targeted
patients with vascular disease, who are often excluded from wound trials. For various
reasons, our population had problems with tissue perfusion, which is typical of a vascular
surgery clinic population. With that, our sample is representative of patients that typically
require acute care vascular services for complex and hard-to-heal wounds. It is possible
that the significantly higher number of patients who had experienced previous toe
amputations in the LFCUD group may represent a subset of patients with specific
vascular pathology and that these wounds may reflect a worsening distal vessel disease.
While this was expected to cast a conservative effect on our results, we were extremely
pleased to find that no wounds became worse, and that we achieved a 31.6% reduction in
four weeks, which is considered impressive for a vascular population. It is not surprising
that there was one death and one toe amputation given the degree of illness in this
population.
A major benefit of LFCUD is the ease of application by a non-physician. Debridement
requires specific knowledge and skills, and carries inherent risks which prohibit the
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availability of the procedure in many areas of practice. Furthermore, there are gaps in
education delivery, and policy, with few definitive protocols available.21 In a supported
environment, the availability of nurse-applied LFCUD allowed for improved access to
care. This benefit was also described for the nurse-applied LFCUD treatment of a peristomal wound, which allowed for an earlier skin graft and decreased hospital stay.53

4.4.6

Limitations

There were several limitations in this study. Patients were recruited with a variety of
wound etiologies related to vascular disease. While it may have been preferable to restrict
the sample to a particular wound etiology, it was considered unlikely that sufficient
participants could be recruited within the catchment area to permit analysis. We were
pleased that our sample was representative of a typical vascular surgery department
population, which was clinically relevant.
We were unable to blind the participants. It is possible that the participants may have
adjusted their response to pain questioning based on attempting to support the study, or in
anticipation of a wound treatment that induces bleeding. The two nurses asked about pain
to encourage open dialogue about the pain experience.
Additionally, the ET RN could not be blinded in order to provide the LFCUD treatments,
which is a common problem for wound trials. That said, every effort to reduce bias was
implemented, including the blinding of the RPN for wound measurements and the ID
physician for consistent antibiotic treatment across groups. While the revPWAT scores
were calculated by the ET RN, the analysis was performed using unidentifiable photos.
The photos were not identifiable by time or by the patient, and—when analyzed—it was
not possible to recall sequential scores in relation to visit number. Additionally, as
recruitment continued, the ET RN could no longer recall the group allocation of many
patients which had to be verified at each clinic visit.
The use of silver alginate dressings or NPWT may have affected healing outcomes. The
antimicrobial properties of silver may have prevented the usual re-growth of bacteria in
the wounds and so reduced our ability to detect the effects on bacteria or biofilm
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reduction. However, since systemic antimicrobial delivery may be further diminished by
PVD and silver is frequently considered as usual care for this population, we considered
it unethical to withdraw all local antimicrobial therapy during the trial. Therefore we
decided to provide every patient with the same dressing protocol.
We chose to administer four weekly treatments, which may have been insufficient to
detect a significant effect. During the treatment phase of the fewer than 15% of patients
failed to attend their visits, and this was within our sample size calculation limitations.
However, even at 12 weeks, the follow-up was not so well attended, which speaks to the
difficulties of gathering evidence of long term treatment effects in a population with
challenging health needs. We acknowledge that the long term follow-up of patients with
multiple health problems can be problematic since there is a high frequency of medical
appointments with different specialists, and the frequency of travel becomes tiring with
advancing disease states. Also, the follow-up period was not long enough to determine
whether wound closure would be more likely with LFCUD treatments.
It is likely that overall there were fewer incidences of wound deterioration than might be
expected due to the intensive visit schedule with examination by an expert team.
However, since treatment and control groups were evaluated by the same team, it is
expected that this would have a moderating effect on the results. Also, since LFCUD was
not combined with other advanced therapies that may be commonly used in an expert
clinic, the full clinical potential of the treatment may not have been realized.

4.5

Conclusion

We found that four weekly LFCUD treatments added to usual care significantly improved
wound appearance in a vascular population (as noted by revPWAT score) and was well
tolerated without adverse events. Our results were inconclusive whether LFCUD
enhances WSA contraction or improves time to complete wound healing. However, since
there was a significant trend in WSA reduction with LFCUD, this aspect warrants future
research since it is possible that a consistent healing trajectory may yield more successful
wound closure.
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We could not determine if four weekly LFCUD treatments significantly reduced bacterial
load or lowered clinical signs of infection in a vascular population. We were unable to
determine if LFCUD could reduce the number of whole patient outcomes at 12 weeks
such as amputations, deaths, ER visits or admission days since there were few in this
study. Importantly, LFCUD did not cause wounds to deteriorate, and did not increase the
number of adverse events.

4.5.1

Clinical Implications and Future Research

Our study found LFCUD is a feasible and well-tolerated method of debridement for a
vulnerable population with vascular disease, who are often excluded from research and
have few treatment options. The improvement of wound appearance is a clinically
important finding since challenging patients may then become eligible for wound closure
by skin graft. Additionally, LFCUD may improve access to debridement procedures since
it was found to be a well-tolerated, was without adverse events, and was feasible to offer
without extensive surgical personnel or resources.
Importantly, we believe that high risk populations with vascular diseases should be
included in future LFCUD trials. Future research to determine if better healing outcomes
or reduced infection may be attained for specific wound types with increased applications
in combination with other therapies and over an extended time. Our study suggests that it
is a safe and efficient method of wound preparation which is well-tolerated and feasible
to apply by the ET RN in a tertiary care vascular wound clinic.
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5

Thesis Discussion

This research was one of the first of a series of works responding to the needs of this high
risk population. This doctoral research, comprised of three distinct clinical studies, has
sought to address the needs of a particular population with challenging health needs. With
a view to improving wound care for patients with vascular disease, we have contributed
to understandings about how to identify and address signs of wound infection and how to
treat wound infection using an ultrasound system of debridement.
Chapter 2 presented our study on the validity of clinical signs of wound infection in
patients with vascular disease. Since patients with vascular disease have a high incidence
of limb threatening infection, the study aimed to develop an assessment tool that would
aid wound care clinicians in detecting infection. The study, again, involved 78 patients
with vascular compromise and a wound located on the lower extremity. The presence or
absence of 13 signs of infection was noted by a single nurse with advanced wound care
training. The sensitivity and specificity of clinical signs of infection either individually or
in combination were compared to the actual infection using as positive tissue biopsy
and/or diagnosis by an infectious diseases physician.
Our study, reported in Chapter 2, found certain clinical signs to be specific (>0.9) but not
very sensitive. Combining three or four clinical signs together improved the specificity,
but did not change the sensitivity. Our results suggest that when clinical signs such as
heat, increasing wound size, wound breakdown, odour, increased serous exudate and
induration are present, the clinician can be confident an infection is present. However,
with such low values for sensitivity, the absence of these clinical signs of infection does
not mean infection is not there. These results demonstrate that clinical tools that have
been used previously to detect infection in other patient populations with chronic wounds
(e.g. diabetic foot ulcers) cannot be applied to this high risk population with vascular
compromise. The poor sensitivity assonated with clinical signs of infection speaks to the
urgent need for an objective point of care test for this population to promote better
outcomes.
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Chapters 3 and 4 focused on evaluating the feasibility and effectiveness of a novel
treatment intervention that uses low frequency ultrasound energy (LFCUD) to remove
excess debris commonly found in wounds with vascular compromise. This therapy
physically removes dead or foreign material from the wound, and is purported to prevent
infection by removing a site for bacterial invasion.
Chapter 3 detailed an initial single arm uncontrolled study involving ten patients with
PVD. The purpose of this pilot study was to assess the feasibility of doing a larger
randomized controlled trial where assessor blinding was involved. Specifically, the effect
of LFCUD on healing outcomes and complication rates (infection, amputation, and
hospital admissions) was evaluated. We also assessed procedural related pain, and the
feasibility of a weekly treatment schedule for outpatients traveling to a clinic for patients
with lower extremity wounds associated with PVD. To prepare for this pilot study using
LFCUD, necessary approvals were secured, a medical directive to allow the nurse
clinician to deliver LFCUD was obtained, and training by the manufacturer (Misonix)
was completed (Plate 1). A treatment procedure that adhered to strict medical asepsis,
equipment sterilization, and used protective equipment was developed and refined.

In this small pilot study—discussed in Chapter 3—it was concluded that LFCUD was
feasible and safe to apply by a nurse specialist in a supported out-patient centre. LFCUD
was well tolerated by patients and a weekly treatment schedule was deemed feasible for
patients attending an outpatient clinic. Wound size reduction after four weekly treatments
was clinically significant (39.4% ± 29.3). These data were then used to calculate a sample
size needed to detect statistically significant differences between LFCUD and UC (see
Appendix 3). The study found a sample size of 32 patients per group or 64 patients in
total would be required to determine a treatment effect.
In Chapter 4, we described an assessor-blinded randomized controlled trial conducted to
compare a group of vascular patients receiving LFCUD and usual care (UC) with a group
of vascular patients receiving UC. Seventy patients with lower extremity wounds and
vascular disease were enrolled over a 13-month period with 68 patients participating in
the trial and 63 patients completing all four weeks of treatment. All subjects underwent
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an initial assessment by a vascular surgeon and an ID physician to confirm healing
potential and assess/treat wound infections. A consistent UC wound program was
developed that included conservative sharp debridement. Patients were then randomly
assigned to either continue UC or also to receive UC and four weekly treatments of
LFCUD delivered directly to the wound bed in order to remove any debris and produce
fresh bleeding. We measured pain, wound size and appearance along with any
complications at Week 0 (baseline), at Week 5 (one week after treatment), and Week 12
(seven weeks after treatment). Again, a total of 63 patients completed four weeks of
treatment and attended 94.5% of scheduled appointments. Missing data for 68 patients
were imputed as last outcome carried forward. Drop-outs were equal between groups and
unrelated to treatment.
As reported in Chapter 4, results from this controlled clinical trial showed LFCUD
significantly improves wound appearance and is well tolerated with minimal bleeding or
pain. While a progressive reduction in wound size was seen in the LFCUD group, the
mean percentage wound surface area was not statistically significant. It is possible that
the LFCUD treatment schedule was not sufficient enough to produce a large enough
change in the treatment group. We found LFCUD treatment improves wound appearance,
is well tolerated, and results in minimal bleeding.
Moving forward, future studies should evaluate a LFCUD treatment with longer
treatment application times (our average treatment time was less than three minutes),
with more frequent appointments (two or more times a week), and/or over longer periods
of time (more than four weeks). By doing a pilot study prior to the controlled clinical
trial, a sample size could be calculated to ensure the number of subjects in the trial is
sufficient to detect a difference in the primary outcome (wound size reduction).
This research involved a group of patients with advancing vascular disease. Based on the
low number of complications, the absence of treatment-related events, and the few
withdrawals, more research evaluating new wound treatments should be conducted on
this high risk population.
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Appendix 1University Original Research Ethics Board Approval Notice

108

Appendix 2 Clinical Site Original Research Ethics Board Approval Notice
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Appendix 3 Sample Size Calculation
The sample size for the randomized controlled trial was initially calculated using
percentage area reduction at four weeks as the primary outcome measure. The minimally
important difference between healers and non-healers was considered as 20% contraction
based on a conservative estimate from available literature of normally perfused
patients.112 Variability within the sample was considered at 10%. Once the pilot data
were analyzed, the minimally important difference of this population estimate remained
at 20% since it was found that the mean WSA reduction which was 39.4%, for which a
20% difference wound render an 19.4% estimation of for non-healers. Because it is
known that only 25% of arterial insufficient wounds heal at six months,113 19.4% was
considered to be an optimistic target for non-healing vascular wounds, and so these
estimations would yield a conservative sample size calculation.113
Therefore sample size =

2(1.96 + 0.84)2 σ2 = 2(1.96 + 0.84)2 102 = 31.36 /group
(δ – M) 2

(20 -10) 2

Using this formula, the sample size was calculated to be 32 patients per group (as
calculated using a 95% confidence interval and continuous data). This calculation was
based on a two-sided analysis (within a superiority design for a conservative assessment),
which was used to identify a significant treatment effect considering p = 0.05 and β = 0.2.
Assuming a 15% drop out rate, this calculation determined that recruitment of 36 subjects
per group would be reasonable to maintain the target of 32 patients in each of the two
groups (64 in total) to determine a significant effect.
1. Cardinal M, Eisenbud DE, Phillips T, Harding K. Early healing rates and wound area
measurements are reliable predictors of later complete wound closure. Wound Repair Regen.
2008;16(1):19-22.
2. Marston WA, Davies SW, Armstrong B, et al. Natural history of limbs with arterial
insufficiency and chronic ulceration treated without revascularization. J Vasc Surg.
2006;44(1):108-114.
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Appendix 4 Sonic One ® Device Illustration
Generator and hand-piece with gold probe
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Inter-changeable Gold Probe

111

Appendix 5 Illustration of cavitation of micro-bubble (implosion) causing debridement of
wound surface

Image courtesy of Misonix, Inc., Farmingdale, NY
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Appendix 6 Image: Amplitude and cavitation (micro-bubbles)

Image courtesy of Misonix, Inc., Farmingdale, NY

113

Appendix 7 Illustration of different probes (from product brochure)
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Plate 1 Photo: Training with the Sonic One ®.
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Plate 2 Photo: Patient receiving LFCUD
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Plate 3 Photo: Pilot patient pre-LFCUD treatment: (Week 0). Open digital amputation
site

Plate 4 Photo: Same patient post-LFCUD treatment: (Week 5)

(Ready for skin graft).
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